Subject Index

Page numbers with prefix S are found in Supplement 1 (January).
Page numbers with prefix B are found in Supplement 2 (August).
Page numbers with prefix C are found in Supplement 3 (December).

A

Acarbose
  antihyperglycemic effect, 667
  Asian multicenter clinical trial, in type 2 diabetes, 1058
  associated hepatotoxicity, 2029
  and carbohydrate intake
    and gastrointestinal symptoms in type 2 diabetes, 1612
    and HbA_{1c} in type 2 diabetes, 1612
  in NIDDM patients with poor control on conventional oral agents, 1154
  safety and efficacy in type 2 diabetes, 2050, 2056
  and serum 1,5-anhydroglucitol concentrations, 465
Accident insurance, diabetes and, 877
ACE gene insertion/deletion polymorphism
  angiotensinogen T235, and albuminuria in type 2 diabetic Chinese, 431
  as risk factor for carotid artery intima-media thickening and hypertension, in young type 1 diabetic patients, 836
ACE inhibitors, and hypoglycemia, 470, 471
N-acetyl glucosaminidase and 1,5-anhydroglucitol and albumin, in NIDDM, 619
Achromatic perimetry, in type 1 diabetic children, 2003
Acute-phase response, and microalbuminuria in NIDDM, 385
Adipose tissue
  and metformin, antihyperglycemic effect, 1301
  subcutaneous, microdialysis of glucose, 1481
Adolescents
  with IDDM
    advanced glycation end product, N^{ε}(carboxymethyl)lysine in, 1997
    coping skills training, 902
    ketoacidosis in, constant infused glucose regimen during recovery phase, 676, 677
    randomized trial of intensive therapy offered to, 213
  nonwhite, and epidemic of diabetes in Allegheny County, Pennsylvania, 1278
  quality of life
    and intensive diabetes management protocols, 885
    personal and family factors, 909
  short-term diabetes in, growth changes and, 1226
Adrenomedullin, levels in type 1 diabetes, 999
Advanced glycation end product(s)
  increased levels, in NIDDM patients with complications, 1027
  N^{ε}(carboxymethyl)lysine, in children and adolescents with type 1 diabetes, 1997
African-Americans
  with α-glucosidase inhibition, chronic treatment, 416
  and albuminuria in type 2 diabetes, 1576
  effects of BMI on diabetes risk, 1828
  glycemic control, identifying, fasting or random glucose for, 501
  hyperfiltration in type 2 diabetes, 2129
  hypertension risk, and type 2 diabetes, 1836
  on Medicare, morbidity, quality of care, and resource utilization, 1090
  NIDDM, physical activity and, 555
  retinopathy
    in type 1 diabetes, 792
    risk in type 2 diabetes, 1230
  waist circumference, and type 2 diabetes, 1836
  women, history of gestational diabetes and metabolic alterations in nondiabetic, 1250
Afro-Caribbeans
  with type 2 diabetes, myocardial infarction in, 1271
Age
  at diagnosis of IDDM, genetically determined, 925
  maternal, association with gestational diabetes mellitus, B14, B44
Alaska-Siberia Project, 563
Alaskan Eskimo, impaired glucose tolerance in, 563
Albumin
  and carotid atherosclerosis and adolescents and young adults with IDDM, 1004
  excretion rate
    enhanced progression, in IDDM in puberty, 1019
    in NIDDM, 1932
Albuminuria
  in African-Americans with short duration of diabetes, 1576
  exercise-induced, lisinopril and, in IDDM, 1345
  in type 2 diabetic Chinese, angiotensinogen T235 and ACE insertion/deletion polymorphisms, 431
Aldose reductase protein content, influence on polyol-pathway metabolites and redox state in erythrocytes, 1014
Aldose reductase inhibitor, and erythrocyte sorbitol concentrations in patients with diabetic complications, 672
Allegheny County, Pennsylvania, epidemic of diabetes in nonwhite adolescents, 1278
α-glucosidase inhibition
  chronic treatment in type 2 diabetic African-Americans, 416
  and impaired glucose tolerance, 1720
  long-term titrated dose, in Hispanic NIDDM patients, 409
  and prevention of type 2 diabetes, 1720
American College of Obstetricians and Gynecologists, B5, B14
  recommendations for classification, diagnosis, treatment, and follow-up of gestational diabetes mellitus, B114
  recommendations for insulin treatment in gestational diabetes mellitus, B94
  recommendations for screening for gestational diabetes mellitus, B15
  recommendations for weight during pregnancy, B133–B134
American Diabetes Association, 157, 179
  annual meeting, 183, 315, 457, 1764, 2023
  aspirin therapy, position statement, S45
  blood glucose monitoring in hospitals, position statement, S78
  Clinical Practice Recommendations, 191, B91, B95; Suppl. 1
  concurrent care, position statement, S82
  Consensus Development Conference on diagnosis of coronary heart disease, 1551
  consensus statements, list, S91
  continuous subcutaneous insulin infusion, position statement, S76
  correctional institutions, management of diabetes in, position statement, S80
  criteria for abnormal glucose tolerance, versus World Health Organization, 1686
  criteria for diagnosis of diabetes
    applied to Canadian native population, 870
    applied to Hong Kong Chinese population, 2094
    relationship with hemoglobin A_{1c} levels, 2198
  and developing world, 191
  Diabetes Control and Complications Trial, implications, position statement, S88
  diabetic nephropathy, position statement, S50
  diabetic retinopathy, position statement, 157, S47
  dietary recommendations for management of gestational diabetes mellitus, B133
  dyslipidemia, management, position statement, 160, S36
  on economic consequences of diabetes mellitus in U.S., 296
  efforts to increase funding for diabetes research, 2152
  exercise, position statement, S40
  fat replacers, position statement, S64
  food labeling, position statement, S62
  foot care, position statement, 2178, S54
  gestational diabetes mellitus, position statement, S60
  glycemia, tests, position statement, S69
  hospital admission guidelines, position statement, S77
  hypoglycemia, and licensure and employment, position statement, S84
  insulin administration, position statement, S72
  lack of agreement between category of impaired fasting glucose and World Health Organization category of impaired glucose tolerance, 1886
  1997 criteria for reversion to nondiabetic status, 1266
  nutrition recommendations and principles, position statement, S32
  nutrition recommendations, translation for health care institutions, position statement, S66
  pancreas transplantation, position statement, S79
  preconception care, position statement, S56
  recommended diagnostic criteria for gestational diabetes mellitus, B5, B14, B33, B91, B114, B118
  recommendations for screening for gestational diabetes mellitus, B15
  risk test, utility of in community screening program, 1029, 1030
  screening for type 2 diabetes, position statement, S20
  self-monitoring of glucose levels in mild gestational diabetes mellitus, position on, B118, B134
  standards and review criteria, S95
  standards of medical care, position statement, S23

American Diabetes Association (continued)
technical reviews, list, S92
third-party reimbursement, position statement, S86
type 1 diabetes, prevention, position statement, S83
U.K. Prospective Diabetes Study, implications, position statement, 2180
unproven therapies, position statement, S85
American Indians
adverse effects of diabetes, and risk factors for cardiovascular disease, 1258
Dartmouth COOP charts' use with, 770
Amino acid metabolism
contribution to gluconeogenesis, B76–B77
exchanges in utero, B70
and fetal body composition, B88, B99, B164
Apoptosis, B62–B63
Amitriptyline, in symptomatic relief of peripheral neuropathy, 1322
Amlodipine, and diabetes control in hypertension and NIDDM, 597, 655
Amputation
lower-extremity, 1, 23
in community, 738
economic benefits of prevention, 1240
ulceration, 42
peripheral arterial occlusive disease as determinant, in foot ulceration, 625
risk, contribution of depth, infection, and ischemia to, 855
Amylin
increase, gestational diabetes and, 668
insulin therapy and, in NIDDM, 810
in type 1 diabetes, 658
Amylin-like peptides
insulin therapy and, in NIDDM, 810
sulfonylurea and, in NIDDM, 810
Anemia, in IDDM patients with epoetin alfa, 423
Angiography, and evaluation of peripheral arterial occlusive disease, 625
Angiotensinogen T235, and ACE insertion/deletion polymorphisms, and albuminuria in type 2 diabetic Chinese, 431
Apolipoprotein E polymorphism, and renal function, in Germans, 994
Apoptosis, B62–B63
Arrhythmia, and mortality after myocardial infarction, 637
Arterial hypertension, familial history, in Brazilian type 2 diabetic patients with nephropathy, 1545
Asian Indians
cardiovascular risk factors in urban, 967
fasting plasma glucose as diagnostic criterion in, 666
Asians, with type 2 diabetes, multicenter clinical trial of acarbose in, 1058
Aspirin therapy
American Diabetes Association position statement, S45
Atherosclerosis
in adolescents and young adults with IDDM, 1004
glucose tolerance and carotid wall thickness in type 2 diabetes, 1812
and glomerular filtration rate in Japanese type 2 diabetic patients, 1848
hormone replacement therapy and carotid wall thickness in women, 1790
International Diabetes Federation Meeting and, 1356
and NIDDM
in Canadian Oji-Cree, 322
gliclazide treatment, 487
Atherosclerosis Risk in Communities Study, 2116
Attentional functioning, in type 1 diabetic patients with and without severe hypoglycemia, 1568
Attitudes, maternal, effect on complications in offspring, B143
Autoimmune polyglandular syndrome, organospecific lymph node enlargement, 1573
Autoimmunity, and intraperitoneal insulin treatment by programmable pump, 2041, 2043
Autonomy, to motivate patients for glucose control, 1644

B

Bacille Calmette-Guérin vaccine, and C-peptide secretion, in newly diagnosed IDDM children, 1691
Bahrainis, high prevalence of diabetes, 936
Becaplermin, and foot ulceration, efficacy and safety, 822
Belgians, glycemic control in type 1 diabetic patients, 2200
Bennewitz, Heinrich Gottlieb, B3, B4
Bergman's minimal model method, B21, B28
β-adrenergic sensitivity
and hypoglycemia, in normal and type 1 diabetic subjects, 1505
and hypoglycemic unawareness, 1939
in type 1 diabetes, 1939
β-cell. *See* Pancreatic β-cell
β-hydroxybutyrate, in early pregnancy, 1978
β-thalassemia, and nephropathy in hypertransfused patients, 1306
β_3-adrenergic receptor, genetic variation, and metabolic phenotypes in Oji-Cree, 851
Bezafibrate Infarction Prevention Trial, 165
BIGPRO1 Study, 1967
Biguanide antidiabetic agents, metformin intoxication, 2036
Birth, seasonality, in childhood diabetes in the Netherlands, 190
Birth trauma. *See also* Pregnancy and perinatal complications
and gestational diabetes mellitus, B6
glycemic control and early delivery as means of avoiding, B113–B116
Birth weight. *See also* Macrosomia
fetal size and gestational diabetes mellitus, B144, B161
glycemic control in pre-conception period and early pregnancy of IDDM women, effect on, 535
long-term effect on children of women with gestational diabetes mellitus, B138–B140, B144
low birth weight, B150–B155
as predictor of metabolic syndrome in postmenopausal women, 1652
Blood glucose analyzer, HemoCue, in research studies, 1369
Blood glucose meters
and glycemic control in type 1 diabetes, 1694
clinical and analytical accuracy, 585
Blood glucose monitoring, in hospitals
American Diabetes Association position statement, S78
Blood glucose values, correlating with HbA_{1c} values, 209
Blood pressure, and nephropathy in elderly Japanese NIDDM patients, 111
Blue-on-yellow perimetry, in type 1 diabetic children, 2003
Body fat, in postmenopausal women with NIDDM, 828
Body mass index, effects on diabetes risk, in black and white Americans, 1828
Body weight
and lifestyle intervention in overweight individuals with family history of diabetes, 350
reducing, and conversion to overt diabetes, 334
Bone age, as determinant of pubertal growth in IDDM, 831
Brazil
American Diabetes Association and World Health Organization glucose tolerance categories, 1889
type 2 diabetes, and familial history of arterial hypertension, coronary heart disease, renal disease, 1545
Breast-feeding
and contraception, B52
effect on children of mothers with gestational diabetes mellitus, B138–B140, B167
Bruneck Study, 221

C

C-peptide concentration
and endothelin 1 levels in android type obesity, 1778
and tumor necrosis factor-α in android type obesity, 1778
C-peptide secretion, in newly diagnosed IDDM children, bacille Calmette-Guérin vaccine, 1691
Calcium antagonists, risk of adverse events, 193, 1779
Caloric restriction, effects on weight loss and glycemic control, in type 2 diabetes, 2
Canadian Oji-Cree
β_3-adrenergic receptor, genetic variation, and metabolic phenotypes, 851
factor V Leiden and vascular disease, 1203
NIDDM, methylenetetrahydrofolate reductase gene, dietary folate, and atherosclerosis, 322
Canadians, native, American Diabetes Association criteria for diagnosis of diabetes, 870
Candidiasis, vulvovaginal, treatment, 451
Cannula occlusion, with use of insulin lispro and insulin infusion system, 874
Capillary blood glucose, use of laser skin perforator for determination, 871
Carbohydrate intake
acarbose
and gastrointestinal symptoms in type 2 diabetes, 1612
and HbA_{1c} in type 2 diabetes, 1612
Carbohydrate metabolism, B33, B34–B35, B37, B85, B87, B132
intolerance in gestational diabetes mellitus, B27, B133, B162
low versus high glycemic indexes, effect on glucose and insulin levels, B107–B111
and maternal-fetal outcomes without gestational diabetes mellitus, B37, B41

Carbohydrate metabolism (continued)
restriction to control glycemia, B133, B165
Toronto Tri-Hospital Gestational Diabetes Project, B34
Cardiomyopathy in gestational diabetes mellitus, B80
Cardiovascular disease
American Diabetes Association 1998 annual meeting and, 1764
ethnicity and, 1271
Helicobacter pylori infection and, 1129
hyperglycemia and, in older women and men, 1236
increased left ventricular mass in type 1 diabetes with nephropathy, 1534
outcomes, in type 2 diabetes, 641
risk factors, adverse effects of diabetes in women, 1258
Cardiovascular events
amlodipine and, in hypertension and NIDDM, 597, 655
association of exercise capacity with complications in NIDDM, 291
fosinopril and, in hypertension and NIDDM, 597, 655
Cardiovascular mortality, in type 2 diabetes, predictors, 1861
Cardiovascular risk
and gestational diabetes mellitus, B21, B167
glucose metabolism and lipid metabolism and, in adult Turner's syndrome, 1062
and hormone replacement therapy in menopause, B54
implantable insulin pump, 1596
and monounsaturated fatty acid–enriched hypocaloric diet, in obese type 2 diabetic patients, 9
risk of mortality, in middle-aged Swedish men, 539
in urban Asian Indians, 967
Care, level of, population-based assessment, in U.S. diabetic adults, 1432
Carotid artery
intima-media thickening
ACE gene polymorphism as risk factor in young type 1 patients, 836
and plaque formation in NIDDM, 323, 324
stiffness
indexes β, association with insulin resistance in NIDDM, 1178
and microalbuminuria in IDDM, 99
Carotid atherosclerosis
in adolescents and young adults with IDDM, 1004
and glucose tolerance in elderly eastern Finnish men, 1349
and hyperinsulinemia, in hypertensive and control subjects, 1188
Carotid wall thickness
glucose tolerance and, in type 2 diabetes, 1812
hormone replacement therapy and, 1790
Carpenter and Coustan
diagnostic criteria for gestational diabetes mellitus, B34, B100, B161, B163
standard for threshold values, B40, B58
Case management, electronic, for diabetes control, 591
Catecholamine levels, and increased plasma pancreastatin-like levels, in gestational diabetes, 1951
Caucasians
effects of BMI on diabetes risk, 1828
hyperinsulinemia, 127
insulin secretion, 127
normal glucose-tolerant relatives of type 2 diabetic subjects, 278
myocardial infarction, in type 2 diabetes, 1271
pancreatic β-cell function, 127
retinopathy
risk in type 2 diabetes, 1230
in type 1 diabetes, 792
women, gestational diabetes testing, 1803
Celiac disease
and diabetic instability, 2192
hypoglycemia and reduction of insulin requirement, 1379, 1380
screening, immunoglobulin A-antiendomysial antibody, 1985
Cellular phones, and interference with portable insulin pumps, 1775
Cerebral function, after hypoglycemia, nocturnal, in IDDM, 341
Cerebrovascular disease, *Helicobacter pylori* infection and, 1129
Ceruloplasmin, and hyperglycemia, in type 2 diabetes, 1525
Cesarean delivery, B2, B6, B7, B100, B126, B164, B165, B166
association with body mass index, B38
association with gestational diabetes mellitus, B75
association with glucose tolerance test, B16, B33, B37–B39
cost-benefit analysis, B128
early labor and glycemic control as means of avoiding, B113–B117
effect of macrosomia, B101
Chest pain, coronary artery bypass, 1603
Childhood diabetes, in China, 525
Childhood IDDM Hokkaido Registry, 1632
Children
diabetes care of, emergency telephone hotline service, 1365
French, glycemic control, 1146
with IDDM
age of onset and prognosis in Japanese, 1674
bacille Calmette-Guérin vaccine, 1691
celiac disease in, hypoglycemia and reduction of insulin requirement, 1379, 1380
C-peptide secretion, 1691
islet cell antibodies, 1824
ketoacidosis, constant infused glucose regimen during recovery phase, 676, 677
neuropsychological complications, 379
transient hypoglycemic hemiparesis, 1567
islet cell antibodies and predicting IDDM, 1670
Mexican, IDDM incidence, 1372
Puerto Rican, IDDM incidence, 744
short-term diabetes, growth changes, 1226
with type 1 diabetes
advanced glycation end product, N^{ε}(carboxymethyl)lysine, 1997
blue-on-yellow and achromatic perimetry, 2003
celiac disease screening, 1985
China
childhood diabetes, 525
type 2 diabetes
albuminuria, angiotensinogen T235 and ACE insertion/deletion polymorphisms, 431
progression to, in high-risk groups, 1183
Chinese
1997 American Diabetes Association diagnostic criteria applied to Hong Kong population, 2094
Cholesterol
and hormone replacement therapy, B53
and high prevalence of diabetes in Bahrainis, 936
Cholesterol and Current Events Study, 164
Chorea, in hyperglycemia, 1777
Cifenline succinate, and dementia in elderly NIDDM patient, 320
Cimetidine, creatinine concentration after administration, and glomerular filtration rate in NIDDM, 216
Classification of diabetes mellitus, report of expert committee, S5
Clinical Practice Recommendations, American Diabetes Association, summary of revisions, S2
Cognitive function, in elderly with impaired glucose tolerance, 398
Common variable immunodeficiency, in IDDM women, 1029
Community nursing service, and dependency in insulin-treated patients, 1567
Community screening program, American Diabetes Association risk test, 1029, 1030
Complications
advanced glycation end products in NIDDM, 1027
association of exercise capacity, in NIDDM, 291
erythrocyte sorbitol concentrations, 672
medical costs, in type 2 diabetes in U.S., 1122
stratifying patients at risk, 1439
Concurrent care
American Diabetes Association position statement, S82
Congenital malformation, association with gestational diabetes mellitus, B11
Consensus Development Conference on Insulin Resistance, 310
Continuing medical education, and attitudes of primary care providers toward diabetes, 1391
Continuous intraperitoneal insulin infusion, in IDDM, 1044
Continuous subcutaneous insulin infusion
American Diabetes Association position statement, S76
and hepatic responsiveness to glucagon in type 1 diabetes, 1627
infection of site, with *Mycobacterium peregrinum*, 191
with insulin lispro, counterregulatory hormone responses, 93
interruption, in acutely decompensated NIDDM, 817
Coronary artery bypass
and chest pain, 1603
and dyspnea, 1603
and physical activity, 1603
Coronary artery disease
diagnosis, dobutamine-atropine stress echocardiography, 1797
in South Indian NIDDM patients, lipoprotein(a) as risk factor, 1819
in type 1 diabetes, and family history of type 2 diabetes, 610

Coronary heart disease
  American Diabetes Association Consensus Development Conference on diagnosis, 1551
  effect of diabetes, B43
  factor V Leiden, 198, 199
  familial history, in Brazilian type 2 diabetic patients with nephropathy, 1545
  hyperglycemia, 321
  insulin, in general population, 221
  management of dyslipidemia in diabetic adults, 160
  prevalence in elderly, 959
  risk factors, 139
    high blood glucose concentration, in middle-aged nondiabetic men, 360
    and lifestyle intervention in overweight individuals with family history of diabetes, 350
    and low-density lipoprotein, 1397
  risk of mortality, in middle-aged Swedish men, 539
  variants of fatty acid-binding protein 2 gene, in nondiabetic subjects and NIDDM patients, 849
Correctional institutions, management of diabetes
  American Diabetes Association position statement, S80
Cortisol, and carotid atherosclerosis and adolescents and young adults with IDDM, 1004
Cost-effectiveness
  of diet and exercise management in gestational diabetes mellitus, B136
  of intervention in women with gestational diabetes mellitus, B12, B116, B129
  of management of gestational diabetes mellitus, B123–B130, B166
    Northern California Program, B124
    New England Program, B124–B125
    Southern California Program, B125
  of NIDDM prevention in women with gestational diabetes mellitus, B12, B20, B22, B43, B50
  of screening for gestational diabetes mellitus, B13, B14, B15, B17
  of tight glycemic control in gestational diabetes mellitus, B99, B101
  of treatment of type 2 diabetes, 464
Cost of diabetes care, 1370, C1, C11, C15, C19
  International Diabetes Federation meeting on, 1198
C-peptide levels and gestational diabetes mellitus, B83
Creatinine concentration, and glomerular filtration rate in NIDDM, 216
Critical-period programming, B160
CSII. *See* Continuous subcutaneous insulin infusion
Cutaneous manifestations, in IDDM, association with diabetes risk factors and microvascular complications, 506
Cyclophosphamide, insulin resistance, type B syndrome, 1217
Cyclosporin A, insulin resistance, type B syndrome, 1217
Cystic fibrosis
  and diabetes, 943, 2199
  diagnosis of diabetes, 671
Cytokines
  association with postpartum diabetes, B44
  and cell viability, B65

D

Dartmouth COOP charts, use with American Indians, 770
Declaration of the Americas on Diabetes, 191, 2204
Delivery, mode and timing. *See* Cesarean delivery *and* Early induction of labor to prevent complications
Dementia, cifenline succinate and, in elderly NIDDM patient, 320
Diabetes
  accident insurance and, 877
  American Diabetes Association criteria for diagnosis, in Canadian native population, 870
  in adults
    family environment, glycemic control, and psychosocial adaptation, 241
  aspirin therapy, S45
  concurrent care, S82
  costs, 1370, C1, C15
    impact in U.S., C11
    limits on provision of care, C15
    patient's perspective, C29
    and treatment, C19
  cystic fibrosis–related
    diagnosis, 671
    identification and treatment, 943
  definition, B3
  diagnosis and classification, report of expert committee, S5
  diagnosis in thalassemia major, 671
  eating disorders and, comorbidity, 1110
  economic consequences, 296, C1, C15, C17
  ethnic and geographic differences, B9
  exercise, S40
  family history, and lifestyle intervention in overweight individuals, 350
  gestational. *See* Gestational diabetes mellitus
  global burden, 1995 to 2025, 1414
  hospital admission guidelines, S77
  hospitalization, in older adults, 231
  of long duration, self-rated health and, 236
  management, in correctional institutions, S80
  and mortality, 1167
    in older adults, 231
  nutrition recommendations, S32
  in offspring of mothers with gestational diabetes mellitus, B6, B34, B138–B140, B142–B148
  overt, conversion to, diet and exercise reducing body weight, 334
  patient's perspective, C29
  predictors
    fructosamine and fasting plasma glucose concentration, 1221
    HbA_{1c} and fasting plasma glucose concentration, 1221
  preexisting, association with acute myocardial infarction, 461
  prevalence, 1414
    in Sweden, 546
    in U.S. adults, 518
    in Veterans Health Administration, 368
    in women of childbearing age, B9
  qualitative research, 1387
  revised etiologic classification, 466, 467, 469
  risk of developing, and changing diagnostic criteria, 1404
  seasonality of birth in childhood diabetes in the Netherlands, 190
  screening
    fasting plasma glucose, 1856
    in obesity, 468
  short-term, and growth changes in children and adolescents, 1226
  standards of medical care, S23
  undiagnosed cases, B9, B10, B11
  unrecognized, among hospitalized patients, 246
  World Health Organization predictions of future increases in frequency, B13
Diabetes Atherosclerosis Intervention Study, 165
Diabetes Attitude Scale, 1403
Diabetes care
  and diabetes research, 2152
  for Medicare beneficiaries, 1282
  pediatric, emergency telephone hotline service, 1365
  third-party reimbursement, S86
  work of American Diabetes Association, 2152
Diabetes Care, state of the journal, 883
Diabetes control, electronic case manager, 591
Diabetes Control and Complications Trial, 143, 1475, 2021
  implications, S88
  nonimplementation in high-risk patients, 1367
Diabetes electronic management system, impact on care of patients in subspecialty diabetes clinic, 972
Diabetes epidemic, response to, 475
Diabetes in Early Pregnancy Study, 1978
Diabetes knowledge test, 706
Diabetes in Pregnancy Center, Northwestern University, B142
Diabetes Prevention Study, B43
Diabetic Pregnancy Study Group, B82, B163
Diabetes research
  funding, 2152
  work of American Diabetes Association, 2152
Diabetes Treatment Satisfaction Questionnaire, 2039
Diabetic hand syndrome, in IDDM, association with diabetes risk factors and microvascular complications, 506
Diabetic mastopathy, 322
  American Diabetes Association meeting and, 183
Diabetic nephropathy. *See* Nephropathy
Diabetic peripheral sensorimotor polyneuropathy, risk factors, 1749
Diabetic retinopathy. *See* Retinopathy
Diagnosis
  of diabetes mellitus, report of expert committee, S5
  of IDDM, age genetically determined, 925
Diagnostic criteria
  changing, and risk of developing diabetes, 1404
  in postpartum testing of women with gestational diabetes, 1579
Diagnostic thresholds, population-based registry, 1374
DIDMOAD syndrome (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness), 38
Diet. *See also* Nutrition
  American College of Obstetricians and Gynecologists recommendations on weight during pregnancy, B133, B138–B140
  American Diabetes Association recommendations, B133

diet therapy for gestational diabetes mellitus, B94, B101, B119, B131–B132, B136
effect of breast-feeding on children of women with gestational diabetes mellitus, B138–B140
effect of caloric restriction on weight loss and glycemic control in type 2 diabetes, 2
effect of carbohydrate type on glucose and insulin profiles, B107–B111
effect of maternal ketonuria on IQ of offspring, B132
euglycemic diet, B133
fat intake as risk factor for NIDDM, B46
glycogen synthase activity in obese patients, 1498
guidelines in gestational diabetes mellitus, B133
to minimize postprandial glucose levels, B132–B133
monounsaturated fatty acid-enriched hypocaloric, effects on cardiovascular risk factors in obese type 2 diabetic patients, 9
multicenter clinical trial of acarbose in type 2 diabetic Asians previously treated with diet, 1058
poor fetal nutrition as risk factor for diabetes in children, B150
postnatal nutrition, B71–B72, B138–B140
and reducing body weight and conversion to overt diabetes, 334
restriction, glycemic response to, in obesity and NIDDM, 687
Third International Workshop-Conference on Gestational Diabetes Mellitus recommendations, B101, B131–B136
Dubos, René, B160
Dobutamine-atropine stress echocardiography, diagnosis of coronary artery disease, 1797
Domperidone, and quality of life, in patients with symptoms of diabetic gastroparesis, 1699
Drug use and costs, among diabetic patients in Germany, 389
Duncan, Matthews, B3
Dyslipidemia, 179
and cardiovascular outcomes in type 2 diabetes, 641
fish oil, 494
management, 1378, 1379
American Diabetes Association position statement, 160, S36
micronized fenofibrate, 2039
Dysphoria, and hospitalization and mortality in older adults, 231
Dyspnea, coronary artery bypass and, 1603

E

Early induction of labor to prevent complications, B114–B116, B164, B166
Eating disorders, comorbidity of diabetes, 1110
Economic consequences of diabetes mellitus in U.S., 296
Education
achievement in children of mothers with gestational diabetes mellitus, B143, B145
in gestational diabetes mellitus, B121
in preventing NIDDM, B47
self-management, national standards, S95
Education curriculum
nutritional, in type 2 diabetes in Hispanics, 896
patient choice, 896
standard, in type 2 diabetes in Hispanics, 896
Elderly
cifenline succinate and dementia, 320
coronary heart disease prevalence, 959
and exercise and well-being, in type 2 diabetic patients, 2196
expenditure patterns, 747
hospitalization, 231
impaired glucose tolerance, cognitive function, 398
insulin resistance, 959
Japanese, glucose tolerance and, insulin receptor substrate-1, codon 972 polymorphism, 753
mortality, 231
NIDDM, GAD antibodies, 675
prevalence of type 2 diabetes, 959
use of services, 747
well-being and treatment satisfaction, 930
Electronic case manager for diabetes control, 591
Electrotherapy, in symptomatic relief of peripheral neuropathy, 1322
Emergency telephone hotline service, and pediatric diabetes care, 1365
Employment/licensure, hypoglycemia and, S84
Endothelial dysfunction
American Diabetes Association meeting and, 183
hyperglycemia and, 183
and hyperhomocysteinemia, in IDDM, 841
tumor necrosis factor-α and, 1778
in type 2 diabetes, 2047
in young type 1 patients, puberty and, 1990
Endothelial function, preserved, in IDDM, 271
Endothelin
1, levels, correlation with C-peptide concentration in android type obesity, 1778
urinary, and carotid atherosclerosis and adolescents and young adults with IDDM, 1004
Endothelium-dependent vascular functions, perindopril and, in NIDDM with hypertension, 631
Energy restriction, effect on lipid levels, in obese type 2 diabetic patients, 695
Environment
versus genes, in influence of diet on body fat, 2069
Epidemiology
American Diabetes Association meeting and, 2023
of IDDM, in Hokkaido, Japan, 1632
International Diabetes Federation meeting on, 1198
Epidemiology of Diabetes Interventions and Complications, 171
Epoetin alfa, and anemia in IDDM, 423
Erectile dysfunction
American Diabetes Association meeting and, 183
evaluation, Rigiscan and, 1159
in Italians, 1973
pharmacological treatment, 188
risk factors, 188
therapy, 188
Erythrocyte
creatine as assessor of HbA_{1c}, in patients with shortened erythrocyte age, 1732
polyol-pathway metabolism and redux state influenced by aldose reductase protein content, 1014
E-selectin, and vascular cell adhesion molecule-1, in NIDDM, 1008
Estrogens
glycemic levels, 1585
postmenopausal, and risk of myocardial infarction, 1117
Ethnicity
age of presentation of gestational diabetes mellitus, B44
association with gestational diabetes mellitus, B44, B162
and cardiovascular disease, 1271
and fetal growth, B100
and glycemic response to exogenous insulin treatment in type 2 diabetes, 510
high prevalence of diabetes in Bahrainis, 936
microalbuminuria, in NIDDM, 385
Etiologic classification, revised, of diabetes mellitus, 466, 467, 469
EURODIAB Study, 1960
Exercise
American Diabetes Association position statement, S40
arm ergometry, B135
capacity, association with diabetic complications in NIDDM, 291
effect on fetal growth, B107, B132
in elderly type 2 diabetic patients, 2196
Fourth International Workshop-Conference on Gestational Diabetes Mellitus, recommendations, B135
glucose and insulin responses to, B107–B111, B135
glycemic control, in type 1 diabetes, 1775
and reducing body weight and conversion to overt diabetes, 334
and well-being, in elderly type 2 diabetic patients, 2196
in women with gestational diabetes mellitus, B2, B46, B50–B51, B107, B109, B110, B135, B136, B165
Expanded Clinical Evaluation of Lovastatin, 169
Extremely low birth weight (ELBW) infant, nutrition in, B71
Eyes, dry, in diabetes, 1375

F

Factor V Leiden
and coronary heart disease, 198, 199
and vascular disease in Canadian Oji-Cree, 1203
Family environment, and glycemic control and psychosocial adaptation of adults with diabetes, 241
Fasting
effects, in diabetic patients during Ramadan, 2033
to identify poor glycemic control in African-Americans, 501
Fasting plasma glucose concentration
criteria, and insulin response in newly diagnosed Japanese patients, 1133
for detecting gestational diabetes, 1246
and diabetes screening in Taiwanese, 1856
and diagnosis of diabetes, 1404
as diagnostic criterion in Asian Indians, 666
and fructosamine, as predictor of diabetes in high-risk subjects, 1221
and glycated hemoglobin, in predicting diabetes, 2032

Fasting plasma glucose concentration (continued)
and HbA_{1c}, as predictor of diabetes in high-risk subjects, 1221
Fat, dietary
influence of genes and environment, 2069
relationship to total and abdominal fat, 2069
Fat mass, subcutaneous, influence of sex differences, on serum leptin concentrations, 1204
Fat replacers, in nutrition therapy
American Diabetes Association position statement, S64
Fatigue, after hypoglycemia, nocturnal, in IDDM, 341
Fatty acid–binding protein 2 gene, variants, and coronary heart disease in nondiabetic subjects and NIDDM patients, 849
Fatty acids, n-3, and glucose metabolism, in type 2 diabetic men, 717
Femoral artery, stiffness indexes β, association with insulin resistance in NIDDM, 1178
Fenofibrate, micronized, dyslipidemia and, 2039
Fetal growth and development, B100
amino acid metabolism, B70, B76–B77, B88, B99, B164
behavior adjustment, B143, B145
and β-cells, B20, B22, B23, B60, B151–B152
body composition, B83, B85, B87–B88, B99, B152, B161
critical-period programming, B160
educational achievement, B143, B145
and effect of fetal/neonatal environment on development of sympathetic nervous system, B156–B160
and effect of maternal diabetes on development of sympathetic nervous system, B159–B160
and elevated HbA_{1c} values, B79
and environmental temperature, B157–B159
and fat mass and fat-free mass, B86
and fibroblast growth factor, B60–B64, B65–B66, B156
and glucose metabolism, B72–B73, B91, B107
glycemic control and early delivery as means of avoiding excessive fetal growth, B113
growth factors in maternal blood as indicators of, B65–B66
and hyperinsulinism, B60, B82–B83
and insulin-like growth factor, B60
and insulin resistance, B151–B152, B153–B154
and insulin secretion, B152–B153
and intellectual development, B143–B144
and islet cells, B61–B65
long-term effects of intrauterine environment during diabetic pregnancy, B138–B140, B142–B148
and maternal exercise, B107
measurement, B102–B104
monitoring, B2, B166
by amniocentesis, B125, B166
by ultrasound, B102–B104, B125, B129–B130, B161, B164, B166
and nerve growth factor, B156
and norepinephrine, B156–B160
nutrition of the fetus, B70
and fetal hyperglycemia, B100
and growth retardation, B70–B71
and low birth weight, B70
and maternal–fetal nutrient transport, B99–B100
and peptide growth factor, B64–B65
and placental metabolism, B70–B71
poor fetal nutrition as risk factor for diabetes, B150
and serine–glycine exchange, B70
observations for clinical use, B83
psychomotor development, B143, B145
Fibrinogen
levels, and insulin resistance, 2040
metabolic syndrome, 649
Fibrinolysis, weight change and metformin, effect on, 1967
Finger infection, resulting from self-monitoring of blood glucose, 1373
Finland
IDDM, seasonal pattern in clinical onset, 1101
insulin secretion, glucokinase gene islet promoter region variant (G→A), at nucleotide −30, 1194
men, carotid atherosclerosis and glucose tolerance in elderly, 1349
Finland–United States Investigation of NIDDM Genetics Study, 949
FINMONICA Myocardial Infarction Register, 69
Fish oil
dyslipidemia and, 494
and glycemic control, 494
Folate, dietary, and NIDDM in Canadian Oji-Cree, 322
Folic acid, supplementation during pregnancy, B167
Food labeling
American Diabetes Association position statement, S62
Foot
arteries, sympathetic function test of vasoconstrictor changes, 1495
skin microcirculation, neuropathy, 1339
Foot care, S54, 2161, 2178
American Diabetes Association meeting and, 183, 2025
American Diabetes Association position statement, 2178, S54
American Diabetes Association technical review, 2161
dynamic forces transmitted through foot, 1955
foot pressure measurement in South Indian NIDDM patients, 1205
high foot pressures, 1714
lower-extremity amputation, economic benefits of prevention, 1240
microangiopathy, skin circulation, laser irradiation and, 580
neuropathy, 1714
sensory testing, 23
sympathetic function test of vasoconstrictor changes in foot arteries, 1495
therapeutic footwear benefit of Medicare, 777
Foot ulceration
amputation and, angiographic evaluation of peripheral arterial occlusive disease and its role as determinant, 625
classification, 681
high foot pressures, 1714
incidence, multicenter study, 1071
maggot therapy, 2030
neuropathy, 1714
power spectral analysis of heart rate variation, 1173
risk factors, multicenter study, 1071
Forearm, skin microcirculation, neuropathy and, 1339
Fosinopril, and diabetes control in hypertension and NIDDM, 597, 655
Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial, 597, 655
France
children, glycemic control, 1146
evaluation of GHb assays by national quality control surveys, 265
Freinkel, Norbert, B1, B4, B75, B142
French EVADIAC Study Group, 325
Fructosamine, and fasting plasma glucose concentration, as predictor of diabetes in high-risk subjects, 1221
Fructose, and stimulation of insulin secretion, 16
F-wave conduction velocity, ratio of, to motor nerve conduction velocity, in neuropathy, 615

G

GAD antibodies, B20
and age at onset of diabetes, 49
and autoimmunity against thyroid, 49
and ICA512/IA-2 antibodies, in IDDM, 49
failure to find at birth in children with diabetes, 197
in NIDDM elderly patients, 675
-65 antibodies
abrupt onset resulting in non-insulin-dependent state, 2037
ketosis and, 2037
γ-glutamyltransferase, and NIDDM risk, 732
Gastric electrical derangement, and gastric emptying delay, in IDDM, 438
Gastric emptying delay, and gastric electrical derangement in IDDM, 438
Gastroparesis, symptoms, domperidone and quality of life, 1699
Gemfibrozil
hypercholesterolemia and, in NIDDM, 477
hyperlipidemia and, in NIDDM, 477
lipid-lowering action, troglitazone and, 2028
Gender, influence on diabetes in patients aged 40–75 years, 250
General practitioners, providing patient information regarding retinopathy, 324
Genes
versus environment, in influence of diet on body fat, 2069
mapping for NIDDM, 949
Genetic heterogeneity, of type 1 diabetes, 658
Genetic susceptibility, to type 2 diabetes, in Mexican-Americans, 80
Germany
apolipoprotein E polymorphism and renal function, 994
prescription drug use and costs, 389
Gestational diabetes mellitus
American Diabetes Association position statement, S60
and amylin increase, 668
association with cardiovascular risk, B21, B80, B167
borderline cases, B33–B41
Cesarean delivery, prevalence, B2, B6, B7, B75, B100, B113–B117, B126, B164–B166
as a concept, not a disease, B7
and congenital malformation, B11
definition, B5, B9, B19, B58, B79, B131, B162

diagnostic criteria in postpartum testing, 1579
etiology and pathogenesis, B19–B24, B58
predictive markers, B20
role of autoimmunity/heredity, B19–B20
role of decreased insulin sensitivity, B20, B22, B23, B151–B152
role of impaired β-cell function, B20, B22, B23, B151–B152
role of insulin secretion, B20–B21, B152–B153
fasting plasma glucose and detection, 1246
findings reported at 1998 American Diabetes Association meeting, 2189
Fourth International Workshop-Conference on Gestational Diabetes Mellitus recommendations
for metabolic management during pregnancy, B164–B166
for postnatal care, B166–B167
for treating perinatal morbidity, B164
glucose intolerance, effects on newborn outcomes, 871
history, and metabolic alterations in nondiabetic African-American women, 1250
history of concept, B3–B4
and hypertension, B27–B32
after pregnancy, B28
association with insulin resistance, B27, B28, B32
before pregnancy, B28
classification/nomenclature problems, B27–B28
distinguished from preeclampsia, B27, B32
during pregnancy, B27, B29–B31
gestational diabetes mellitus as a prognostic factor, B32
World Health Organization criteria, B27
and increased morbidity in pregnancy, B7
and increased neonatal morbidity, B79–B83, B91
increased plasma pancreastatin-like levels in, 1951
ketoacidosis during, 1031
long-term consequences, B2, B138
management, B113–B116
prevalence, B4, B6, B9, B161
in African-Americans, B11, B28
in Caucasians, B11
in Chinese-Americans, B11
ethnic and geographic differences in, B4, B11, B13, B19, B44
in Indians, B11
in Israeli Bedouins, B11
in Italians, B11
in Pima Indians, B138, B140
in Vietnamese, Indians, Africans, and Chinese in Australia, B11
in Zuni Indians, B11
previous
impaired endothelium-dependent vasodilatation in women with, 2111
relationship of risk to glucose level, B7
risk factors, B11, B12, B14, B15, B44–B46
screening and diagnostic criteria, 674, B11, B15, B43, B50, B58, B161, B162
accuracy and precision, B16
alternative screening tests, B17
as defined by American College of Obstetricians and Gynecologists, B5, B14, B114
as defined by American Diabetes Association, B5, B15, B33, B91, B114, B118
as defined by First International Workshop-Conference on Gestational Diabetes Mellitus, B1
as defined by Fourth International Workshop-Conference on Gestational Diabetes Mellitus, B2, B58, B131
as defined by Second International Workshop-Conference on Gestational Diabetes Mellitus, B1, B19, B33
as defined by Third International Workshop-Conference on Gestational Diabetes Mellitus, B2, B19, B23, B163
as defined by Oxford Database on Effective Care in Pregnancy and Childbirth, B15
as defined by World Health Organization, 32, B6, B13, B15–B16, B43
cost-effectiveness, B12, B116, B123–B130, B136, B166
cost of screening, B14, B15
fasting versus fed state, B15, B34, B41, B119–B120, B127, B165
glycated proteins, B16
population-specific, B6–B7, B124, B138
related to time of gestation, B15
reproducibility, B15
sensitivity and specificity, B163
testing, 1789
in lean young Caucasian women, 1803
75-g glucose tolerance test, 1807
GHb
assays, evaluation in France by national quality control surveys, 265
percent total compared with percent total HbA_{1c}, 1475
Girth, as predictor of metabolic syndrome in postmenopausal women, 1652
Gliclazide, in NIDDM, normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-α, 487
Glimepiride, insulin treatment with 70/30 insulin, 1052
Glipizide, and insulin, in type 2 diabetes, 574
Glomerular charge, assessed by changes in salt intake in type 2 diabetes, 482
Glomerular filtration rate
in Japanese type 2 diabetic patients, link to atherosclerosis, 1848
in NIDDM, estimating from plasma creatinine concentration after cimetidine administration, 216
and urinary albumin excretion rate, in single-kidney type 2 diabetic patients, 1521
Glomerular filtration status, determining, in newly presenting type 2 diabetic subjects, 1893
Glomerular size selectivity, assessed by changes in salt intake in type 2 diabetes, 482
Glu^{298}→Asp (894G→T) mutation
and vascular complications, 2195
Glucagon, continuous subcutaneous insulin infusion, in type 1 diabetes, 1627
Glucagon-like peptide 1, influence on fasting glycemia in type 2 diabetic patients, 1925
Glucokinase, B21–B22
Glucokinase gene islet promoter region variant (G→A), at nucleotide −30, and insulin secretion in Finns, 1194
Glucose
concentration
hormone replacement therapy and, 1589
as risk factor for mortality in middle-aged nondiabetic men, 360
fasting plasma
and diabetes screening in Taiwanese, 1856
and diagnosis of diabetes, 1404
and glycated hemoglobin in predicting diabetes, 2032
impaired fasting
as defined by American Diabetes Association, 1886
in U.S. adults, 518
microdialysis, in subcutaneous adipose tissue, 1481
postprandial plasma, variation of associated with standardized mixed meal test versus 75 g oral glucose, 336
self-monitoring
development of a scale to measure adherence, 1046
finger infection, 1373
in type 1 diabetes, 461
self-monitoring blood glucose meters, 1919
testing, improved methods, 2186
Glucose control
nighttime, insulin lispro and, 32
supporting autonomy to motivate patients, 1644
Glucose counterregulation, and glycemic control during hypoglycemia in NIDDM, 1330
Glucose intolerance
American Diabetes Association criteria, 1027
adverse outcomes compared with normal tolerance, B13, B161
in Alaskan Eskimo, 563
α-glucosidase inhibitor and, 1720
and carotid wall thickness, 1812
in children of women with gestational diabetes mellitus, B146–B147
and cognitive function in elderly, 398
ethnic and geographic differences, B9, B10, B19
and exercise, B135
level in gestational diabetes mellitus compared with normal pregnancy, B19, B43
in NIDDM, insulin receptor substrate-1, codon 972 polymorphism in, 753
as predictor of postpartum diabetes, B43, B50, B166–B167
in pregnant women, effects on newborn outcomes, 871
prevalence, B9, B10, B19, B131, B167
in Aboriginal Australians, B9
in Bantu, B9
greater than prevalence of diabetes in women of childbearing age, B9, B13
in Mapuche Indians, B9
in Nauruans, B9
in Pima Indians, B9
in rural India, B9
in rural native Hawaiians, 549
in Singapore Chinese, B9
in Singapore Malays, B9
in Sri Lanka, B9
screening for, B1, B11, B14–B17, B33–B41, B43, B163
as sequela of suboptimal fetal growth, B150–B154

Glucose intolerance (continued)
retinopathy prevalence, 1664
in U.S. adults, 518
World Health Organization definition, B50
Glucose levels
and carbohydrate metabolism, B107–B111, B133, B165
fasting versus fed state, B15, B34, B41, B119–B120, B127, B165
Fourth International Workshop-Conference on Gestational Diabetes Mellitus recommendations, B134–B135
Glucose metabolism
and cardiovascular risk factors, in adult Turner's syndrome, 1062
and lipid metabolism, in adult Turner's syndrome, 1062
intake of n-3 fatty acids and, in type 2 diabetic men, 717
Glucose tolerance
and carotid atherosclerosis, in elderly eastern Finnish men, 1349
categories
as defined by American Diabetes Association and World Health Organization, in Brazilians, 1889
as defined by World Health Organization, 1886
as defined by American Diabetes Association, in Brazilians, 1889
and hypertension, dipper and nondipper, 1743
insulin sensitivity, 673
in Japanese, homeostasis model assessment, 673
oral test for diabetes screening and diagnosis, 1215
in pregnant women, pancreatic β-cell function in, 403
test, 75-g, 1807
GLUT4, intake of n-3 fatty acids and, in type 2 diabetic men, 717
Glutamic acid decarboxylase antibodies, influence on diabetes in patients aged 40-75 years, 250
Glycated hemoglobin
biological variation, 261
utility, 1578
Glycation, International Diabetes Federation meeting on, 1560
Glycemia
level, effects on mortality, 1167
tests
American Diabetes Association position statement, S69
Glycemic control
in adults, family environment and, 241
in African-Americans, fasting or random glucose for identifying, 501
allopurinol and, 192
in Belgian type 1 diabetes patients, 2200
compared with French patients, 2201
and birth size, B144, B152
and diabetic complications, C39
and cutaneous manifestations in IDDM, association with diabetes risk factors and microvascular complications, 506
diabetic peripheral sensorimotor polyneuropathy and, 1749
and early delivery as means of preventing birth-related complications, B113–B116
effect of calorie distribution, B133
effect of exercise and diet, B111, B165
effect on neonatal morbidity, B81, B91, B113
electronic case manager, 591
E-selectin and vascular cell adhesion molecule-1 in NIDDM and, 1008
exercise and, in type 1 diabetes, 1775
factors associated with, in French type 1 children, 1146
fish oil and, 494
and gestational diabetes mellitus, B12, B91–B96, B99–B100, B131, B135, B164
glipizide and insulin and, in type 2 diabetes, 574
and glucose counterregulation during hypoglycemia in NIDDM, 1330
HbA_{1c} improvement, insulin lispro and, 977
home blood glucose meters, B16–B17
and hypoglycemia, protective responses against, in type 2 diabetes, 283
insulin and glipizide and, in type 2 diabetes, 574
insulin aspart and, in type 1 diabetes, 1904
and insulin doses, B134
insulin lispro and, 93
insulin treatment and, with evening 70/30 insulin plus glimepiride versus insulin alone, 1052
intake of n-3 fatty acids and, in type 2 diabetic men, 717
laboratory methods of measurement, B6
lipoprotein(a) and, in type 1 diabetes, 1517
maternal, association with pregnancy outcome, B12, B72–B73, B138
metformin and, 87
in insulin-treated NIDDM, 701
and mortality risk, 331
and nephropathy in elderly Japanese NIDDM patients, 111
in NIDDM, progression of microalbuminuria and, 1932
and nuclear factor-κB binding activity in peripheral blood mononuclear cells, in type 1 diabetes, 1310
postpartum, B44, B135
and pre-conception period and early pregnancy, effect on birth weight, in women with IDDM, 535
and pregnancy in IDDM, 374
and quality of life in type 2 diabetes, C44
and retinopathy in Koreans with NIDDM, 134
sulfonylurea and, in type 2 diabetes, 1462
self-monitoring, B91, B99, B118–B121, B124, B165
American Diabetes Association position, B118, B134
controversy regarding, B118
cost, B120–B121
effect on patient compliance, B96–B97, B118, B120
in insulin therapy, B91, B101, B118, B119
Jovanovich-Peterson recommendations, B118
timing, B119–B120
use of memory reflectance meter, B91, B94
target levels, effect on well-being in type 2 diabetes, 2085
Third International Workshop-Conference on Gestational Diabetes Mellitus recommendations, B101–B102, B107–B111
tight, cost-effectiveness in gestational diabetes mellitus, B99, B101
timing, B129
and HbA_{1c} improvement and, 977
in obese patient with insulin-requiring type 2 diabetes, 1575
troglitazone and, in type 2 diabetes, 1462
in type 1 diabetes, blood glucose meters with storage capability and computer-assisted analyses and, 1694
in type 2 diabetes
effects of caloric restriction on, 2
in Koreans, microalbuminuria and, 530
well-being and symptoms in relation to, 919
Glycemic excursions
voglibose and, in NIDDM, 256, 1206
Glycemic levels, estrogens and, 1585
Glycemic response
to diet restriction, in obesity and NIDDM, 687
to exogenous insulin treatment in type 2 diabetes, ethnicity and, 510
meal dilution, 711
to weight loss, in obesity and NIDDM, 687
Glycogen synthase activity, irreversibility of defect in, from obese NIDDM patients, 1489
Growth factors. *See* Cytokines

H

Hawaiians, rural native, glucose intolerance in, 549
HbA_{1c}. *See* Hemoglobin A_{1c}
HDL. *See* High-density lipoproteins
Health care institutions, nutrition recommendations, S66
Hearing loss, and NIDDM, 1540
Heart rate variability
lower, in metabolic syndrome, 2116
Heart rate variation, power spectral analysis, in patients with foot ulceration, 1173
Helicobacter pylori infection
and cardiovascular disease, 1129
and cerebrovascular disease, 1129
Helsinki Heart Study, 165, 166
Helsinki Policemen Study, 360
Hemiparesis, transient hypoglycemic, in IDDM children, 1567
Hemochromatosis candidate gene, mutations in HFE, in NIDDM, 1371
HemoCue blood glucose analyzer, in research studies, 1369
Hemoglobin A_{1c}
biological variation in type 2 diabetes, 261
and American Diabetes Association criteria for diagnosis of diabetes, 2198
correlating values of with average blood glucose values, 209
as determinant of pubertal growth in IDDM, 831
determinations of by immunoassay, effects of sickle cell trait and hemoglobin C trait on, 983
erythrocyte creatine assessment of, in patients with shortened erythrocyte age, 1732
and fasting plasma glucose concentration, as predictor of diabetes in high-risk subjects, 1221
fish oil and, 494
insulin lispro and, in IDDM, 977
percent total compared with percent total GHb, 1475
reference range, accounting for age and sex,

2193
in screening for diabetes, 1577
and uremia, measured by high-performance liquid chromatography, 463
Hemoglobin C trait, effects on determinations of HbA_{1c} by immunoassay, 983
Hepatitis
fulminant, troglitazone-induced, 2140
Hepatocyte growth factor
in vitreous fluid of patients with retinopathy, 1759
Hepatocyte nuclear factor-1α/MODY3, missense mutation in homeodomain of, 1569
Hepatotoxicity, acarbose-associated, 2029
HFE, mutations in, in NIDDM, 1371
High-density lipoproteins, fractional esterification rate, in type 2 diabetes, 139
Hispanics
coronary heart disease in, prevalence, 959
insulin resistance in, prevalence, 959
NIDDM, α-glucosidase inhibition in, 409
type 2 diabetes in
diabetes education curriculum and, 896
prevalence, 959
HLA antigens, association with gestational diabetes mellitus, B19
HOE-901 biosynthetic insulin analog, 2187
Hoet, J.P., B4
Homeostasis model assessment, use, 2191
Homocysteine, concentrations of, in type 1 patients, 1843
Hong Kong Chinese
paired value of fasting plasma glucose and glycated hemoglobin in predicting diabetes in, 2032
predicting diabetes in high-risk, 1221
Hoorn Study, 1686
Hormone replacement therapy
in adult Turner's syndrome, 1062
and carotid wall thickness in women, 1790
glucose concentrations and, 1589
and risk of myocardial infarction, 1117
Hormone responses, counterregulatory, continuous subcutaneous insulin infusion with insulin lispro and, 93
Hormones
as risk factors for postpartum diabetes, B50–B55, B58
association with insulin resistance, B50
and cholesterol, B53
exposure
from contraceptives, B51–B52, B58, B166
from hormone replacement therapy, B52–B54, B58
from progestin-only contraceptives, B52, B166
in rats, B22
from subsequent pregnancy, B58
and growth metabolism, B153–B154
replacement therapy and cardiovascular risk, B54
Hormone-sensitive lipase, intake of n-3 fatty acids and, in type 2 diabetic men, 717
Hospital admission guidelines for diabetes mellitus
American Diabetes Association position statement, S77
Hospitalized patients, unrecognized diabetes among, 246
Hospitals, bedside blood glucose monitoring
American Diabetes Association position statement, S78
Hydrogen peroxide, increased formation in polymorphonuclear leukocytes of IDDM patients, 326, 327
Hydroperoxides, insulin treatment in IDDM and, 1295
Hypercholesterolemia
acarbose and, 667
gemfibrozil and, in NIDDM, 477
risk, in middle-aged Swedish men, 539
simvastatin and, in NIDDM, 477
Hyperfiltration
in African-Americans with type 2 diabetes, 2129
Hyperglycemia
burden of, C32
and cardiovascular disease, in older women and men, 1236
chorea in, 1777
compositional lipoprotein abnormalities and, predictors of cardiovascular mortality in type 2 diabetes, 1851
and coronary heart disease, 321
dissociation of microangiopathy and macroangiopathy in type 2 diabetes and, 1451
fetal, B100
measurement of insulin levels in amniotic fluid, B102
as risk factor for fetal morbidity, B100–B101
ultrasound assessment and macrosomia, B102, B103–B104
maternal
and fetal growth, B70
and gestational diabetes mellitus, B99
as risk factor for NIDDM, B50
threshold for gestational diabetes mellitus screening, B58
and meal-generated oxidative stress in type 2 diabetes, 1529
and mortality, all-cause and cardiovascular, 1167
nuclear factor-κB binding activity in peripheral blood mononuclear cells, in type 1 diabetes, 1310
oxidative stress at onset and in early stages of type 1 diabetes in children and adolescents, 1736
risk in children of women with gestational diabetes mellitus, B138–B140
serum ceruloplasmin and, in type 2 diabetes, 1525
and unrecognized diabetes among hospitalized patients, 246
and vulvovaginal candidiasis, 451
Hyperglycemic glucose clamps, and assessment of insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects, 278
Hyperhomocyst(e)inemia
and endothelial dysfunction in IDDM, 841
and microalbuminuria, 1028
Hyperinsulinemia
and carotid atherosclerosis in hypertensive and control subjects, 1188
in Caucasians, 127
and fetal macrosomia, B82
in offspring of NIDDM parents, 76
in Pima Indians, 127
in South Asians, 127
Hyperlipidemia
gemfibrozil and, in NIDDM, 477
simvastatin and, in NIDDM, 477
Hyperlipidemia in Diabetes Investigators Study, 168
Hypertension
ACE gene polymorphism as risk factor for in young type 1 patients, 836
arterial, familial history of, in Brazilian type 2 patients with nephropathy, 1545
as defined by the World Health Organization, B27
dipper, glucose tolerance and, 1743
microalbuminuria in IDDM and, 99
in NIDDM
carvedilol and endothelium-dependent vascular functions in, 631
Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial, 597, 655
perindopril and endothelium-dependent vascular functions in, 631
nondipper, glucose tolerance and, 1743
in pregnancy, B27–B32
association with IDDM, B29
compared with gestational diabetes mellitus, B28, B29
as defined by the American College of Obstetricians and Gynecologists, B27
as defined by the International Society for the Study of Hypertension in Pregnancy, B27
and perinatal mortality, B27, B166
and risk of future hypertension, B31
and risk of mortality in middle-aged Swedish men, 539
in type 2 diabetic Koreans, microalbuminuria and, 530
Hypertransfused patients, with β-thalassemia, nephropathy in, 1306
Hypertriglyceridemia, fish oil and, 494
Hypocaloric diet, monounsaturated fatty acid-enriched, effects on cardiovascular risk factors in obese type 2 diabetic patients, 9
Hypoglycemia
ACE inhibitors and, 470, 471
asymptomatic, in patient taking beta-blocking medication, 2197
and attentional functioning in type 1 diabetes, 1568
and autonomic neuropathy in type 1 diabetes, 1960
and β-adrenergic sensitivity in normal and type 1 subjects, 1505
and beta-blocking medication, 2197
counterregulatory responses to, and fetal growth in IDDM pregnancy, 199, 200
and employment/licensure
American Diabetes Association position statement, S84
findings reported at 1998 American Diabetes Association meeting, 2188
glycemic control and, in type 2 diabetes, 283
in IDDM, risk for severe, 1870
and insulin lispro, 93
in type 1 diabetes, 1726
in NIDDM, glycemic control and glucose counterregulation during, 1330
nocturnal, in IDDM, 341
after pancreas transplantation, 1944
preprandial, after insulin lispro administration, 1777, 1778
reduction of insulin requirement as sign of celiac disease, 1379, 1380
in type 1 diabetes, 658

Hypoglycemia (continued)
in type 1 diabetes (continued)
continuous subcutaneous insulin infusion, effect on hepatic responsiveness to glucagon in type 1 diabetes, 1627
unawareness, β-adrenergic sensitivity in type 1 diabetes and, 1939

I
ICA. *See* Islet cell antibodies
IDDM, B9. *See also* Diabetes *and* Type 1 diabetes
in adolescents
carotid atherosclerosis and, 1004
metabolic control and quality-of-life self-assessment, 915
quality of life and, 909
randomized trial of intensive therapy offered to, 213
age at diagnosis genetically determined, 925
albumin excretion in puberty and, 1019
albuminuria in, lisinopril and, 1345
anemia in, treatment with epoetin alfa, 423
association with gestational diabetes mellitus, B19, B20, B166
childhood
age of onset and prognosis, 1674
and bacille Calmette-Guérin vaccine, 1691
celiac disease and, hypoglycemia and reduction of insulin requirement, 1379, 1380
in China, 525
and C-peptide secretion, 1691
islet cell antibodies and, 1670, 1824
ketoacidosis in, constant infused glucose regimen during recovery phase, 676, 677
neuropsychological complications, 379
newly diagnosed
Puerto Rican, 744
transient hypoglycemic hemiparesis, 1567
counterregulatory hormone responses, after continuous subcutaneous insulin infusion with insulin lispro, 93
cutaneous manifestations in, association with diabetes risk factors and microvascular complications, 506
diabetic hand syndrome in, association with diabetes risk factors and microvascular complications, 506
distortion-product otoacoustic emissions and selective sensorineural loss, 1317
endothelial dysfunction, 841
endothelial function, preserved, 271
epidemic, in nonwhite adolescents in Allegheny County, Pennsylvania, 1278
epidemiology, in Hokkaido, Japan, 1632
GAD antibodies and, 49
gastric emptying delay and gastric electrical derangement in, 438
HbA_{1c} improvement, insulin lispro and, 977
hydrogen peroxide, increased formation of in polymorphonuclear leukocytes of, 326, 327
hyperhomocysteinemia in, 841
hypoglycemia
nocturnal, 341
risk for severe, 1870
ICA512/IA-2 antibodies and, 49
incidence in Mexican children, 1372
and increased carotid artery stiffness in microalbuminuric patients with, 99
insulin lispro, 1044
meal composition and, 26
time of administration, 26
lisinopril and
effect on progression to macroalbuminuria in, 104
exercise-induced albuminuria in, 1345
microalbuminuria in, hydroperoxides and intensified insulin treatment, 1295
muscular endurance in, 597
nephropathy and, 104
muscular endurance in, 597
new-onset, effect of insulin on lipoprotein(a) in, 866
nifedipine and, effect on progression to macroalbuminuria in, 104
in pregnancy, fetal growth and counterregulatory responses to hypoglycemia in, 199, 200
puberty and growth in, determined by HbA_{1c} levels, sex, bone age, 831
retinopathy and improved visual function in, 2007
role of self-monitoring of glucose levels in management, B118
seasonal pattern in clinical onset of, in Finland and Sardinia, 1101
in women
glycemic control in pre-conception period and early pregnancy, effect on birth weight, 535
impact of pregnancy on glycemic control in, 374
in young adults, carotid atherosclerosis and, 1004
IGF. *See* Insulin-like growth factor
Inheritance, role in gestational diabetes mellitus, B19
Immune therapy, in type 1 diabetes, 658
Immunoglobulin A-antiendomysial antibody, celiac disease screening and, in North American children with type 1 diabetes, 1985
Impaired glucose tolerance (IGT). *See* Glucose intolerance
Information technology, International Diabetes Federation meeting on, 1198
Insulin
action, and vanadyl sulfate, 2194
administration
American Diabetes Association position statement, S72
animal, transferring to human, 196
concentration and birth size, B144, B147
concentrations of, hormone replacement therapy and, 1589
continuous subcutaneous infusion, S76
effect on hepatic responsiveness to glucagon in type 1 diabetes, 1627
and coronary heart disease, in general population, 221
daytime NPH, insulin lispro and, 1707
effect on lipoprotein(a), in new-onset IDDM, 866
and fetal development
insulin-like growth factor, B60
insulin resistance, B151–B152, B153–B154
insulin secretion, B151–B152, B153–B154
insulin sensitivity and fetal body composition, B88
and glipizide, in type 2 diabetes, 574
HOE-901 biosynthetic analog, 2187
human regular
compared with insulin lispro, after interruption of continuous subcutaneous insulin infusion, in acutely decompensated NIDDM, 817
in IDDM, 1044
transferring from animal, 196
implantable pump, local adverse events associated with long-term use of, 325
inhaled, 2187
intraperitoneal treatment by programmable pump, autoimmunity and, 2041, 2043
increased need during pregnancy, B134–B135
insulin therapy
as replacement for diet therapy, B94–B96
as treatment for gestational diabetes mellitus, B1, B91–B96, B124–B125, B134, B165
association with gestational diabetes mellitus, B50, B92–B94
association with hormones, B50
effect of postpartum diabetes incidence, B44
Fourth International Workshop-Conference on Gestational Diabetes Mellitus treatment recommendations, B134
and hypertension, B30
prevalence, B20
neutral protamine lispro, time-action profile of premixed, 800
NPH, mixed with insulin lispro, 2098
in obesity treatment, with evening 70/30 insulin plus glimepiride, 1052
soluble, metabolic effect, 1910
sulfated, 1571
transferring from animal to human, in aged type 1 patients, 196
-treated type 2 diabetic patients, troglitazone and, 1455
Insulin aspart
and glycemic control in type 1 diabetes, 1904
metabolic effect, 1910
Insulin autoantibodies, B20, B162
Insulin-like growth factor (IGF)
and fetal development, B61
inhibition of apoptosis, B65
interaction with insulin, B61
Insulin receptor binding, B22
effect of hormones, B23
Insulin infusion system, cannula occlusion with use of, 874
Insulin-like growth factor treatment, in type 1 diabetes, 658
Insulin lispro
action profile when mixed with NPH insulin, 2098
blood glucose control, nighttime, 32
cannula occlusion with use of, 874
caution regarding use of, 462
compared with human regular insulin, after interruption of continuous subcutaneous insulin infusion, in acutely decompensated NIDDM, 817
continuous subcutaneous infusion of, effect on hepatic responsiveness to glucagon in type 1 diabetes, 1627
counterregulatory hormone responses after continuous subcutaneous insulin infusion with, 93
daytime NPH insulin in patients using, 1707

external pump for, in IDDM, 977
and glucose control, nighttime, 32
HbA_{1c} improvement and, in IDDM, 977
health-related quality of life and, 1203
hypoglycemia, effect on in type 1 diabetes, 1726
in IDDM, with delayed absorption of subcutaneously applied human regular insulin and complicated intraperitoneal insulin infusion, 1044
insulin resistance and, glycemic control in obese patient with insulin-requiring type 2 diabetes, 1575
meal composition and, 26
not suitable for implantable pumps, 867
optimization of evening dose in patients using, 1162
postprandial, 570
preprandial hypoglycemia after administration, 1777, 1778
results reported at 1998 American Diabetes Association meeting, 2187
time of administration, 26
time-action profile of premixed, 800
Insulin pen, biologic material in needles and cartridges after injection with, 1502
Insulin pump
cellular phone interference with, 1775
Veterans Affairs Implantable study, 1596
Insulin receptor substrate-1, codon 972 polymorphism, and impaired glucose tolerance in NIDDM, 753
Insulin release, first-phase, physiological importance of in elderly type 2 diabetic patients, 1326
Insulin resistance
and adipocytes, B23
in Asian Indians, cardiovascular risk factors and, 967
and Asp905Tyr polymorphism of gene for skeletal muscle-specific glycogen-targeting subunit of protein phosphatase 1, in NIDDM in Japanese, 1086
association with low birth weight and diabetes, B152, B154
and cardiovascular risk factors in urban Asian Indians, 967
Consensus Development Conference on Insulin Resistance, 310
fibrinogen levels and, 2040, 2041
and free fatty acids, B23
in gestational diabetes, 1951
in gestational diabetes mellitus and hypertension in pregnancy, B28, B30–B31
hepatic, γ-glutamyltransferase, 732
insulin lispro and, glycemic control in obese patient with insulin-requiring type 2 diabetes, 1575
interferon-α and type 1 diabetes and, 1774
metformin and, effect on fibrinolysis and von Willebrand factor in obese nondiabetic subjects, 1967
in Mexican-Americans, B152
in NIDDM, stiffness indexes β of carotid and femoral arteries, 1178
in nonwhite Hispanics, B152
platelet sensitivity and, in lean NIDDM, 121
prevalence in elderly, 959
syndrome
serum ferritin as component of, 62
weight gain and, 1637
troglitazone and LDL proportion and resistance to oxidation in obese subjects, 796
type B syndrome, treatment with plasmapheresis, cyclophosphamide, and cyclosporin A, 1217
Insulin Resistance Atherosclerosis Study, 161, 1790, 1812
Insulin response, and fasting plasma glucose, criteria for, in Japanese, 1133
Insulin secretagogues
fructose, 16
protein, 16
Insulin secretion, B21
in Caucasians, 127
in Finns, glucokinase gene islet promoter region variant (G→A), at nucleotide −30, 1194
impaired, in Japanese diabetic subjects, 2034
and induction of β-cell rest in type 1 diabetes, 427
in normal glucose-tolerant relatives of type 2 diabetic subjects, 278
in Pima Indians, 127
protein ingestion and, 16
in South Asians, 127
stimulation by fructose, 16
type 2 diabetes and obesity and, 1680
voglibose and, in NIDDM, 256
Insulin sensitivity
and gestational diabetes mellitus, B1, B20, B20–B23, B28
glucose tolerance and, 673
homeostasis model assessment of, 673
and LDL size distribution, 2077
resistance training and, in NIDDM, 1353
voglibose and, in NIDDM, 256
Insulin therapy
amylin and amylin-like peptide concentrations and, in NIDDM, 810
intensified, and quality of life determinants, 1876
in type 2 diabetes, well-being and symptoms in relation to, 919
Insulin treatment
exogenous, in type 2 diabetes, ethnicity and glycemic response to, 510
in type 1 diabetes, 658
intensive
and E-selectin and vascular cell adhesion molecule-1 in NIDDM, 1008
and hydroperoxides in plasma, 1295
and macrovascular disease, 669
Insurance, third-party reimbursement, S86
Intellectual development in children of mothers with gestational diabetes mellitus, B143–B144
Intensive therapy, problems with, 2021
Interferon-α, type 1 diabetes and, 1774
International Diabetes Federation Meeting, 658, 860, 1024, 1198, 1356, 1560
International Workshop-Conference on Gestational Diabetes Mellitus
First, B1, B5
definition of gestational diabetes mellitus, B1, B5
Fourth, B1, B2, B4, B58–B59, B131–B136, B161–B167
introduction to, B1–B2
summary of, B2, B131–B136, B161–B167
Second, B1
Third, B1, B2, B101, B118
Intravenous glucose tolerance test, B21
Ischemic heart disease, in men, leptinemia and, 782
Islet amyloid pancreatic polypeptide or amylin, B20
Islet cell antibodies, B20
512/IA-2 antibodies
and age at onset of diabetes, 49
and autoimmunity against thyroid, 49
and GAD antibodies, in IDDM, 49
in IDDM white and black children and adolescents, 1824
influence on diabetes in patients aged 40-75 years, 250
and predicting IDDM in children, 1670
screening, for risk assessment of type 1 diabetes in relatives, 1445
Islet transplantation, in type 1 diabetes, 658
Isradipine, in prediabetic hypertensive subjects, 2103
Italian Microalbuminuria Study Group in IDDM, 104
Italians, erectile dysfunction in, 1973

J

Jamaicans
hypertension risk in, and type 2 diabetes, 1836
waist circumference of, and type 2 diabetes, 1836
Japanese
Asp905Tyr polymorphism of gene for skeletal muscle-specific glycogen-targeting subunit of protein phosphatase 1, in NIDDM, 1086
Childhood IDDM Hokkaido Registry, 1632
children, age of onset and prognosis of IDDM in, 1674
diabetic subjects, insulin secretion in, 2034
elderly, glycemic control and blood pressure in development and progression of nephropathy in, 111
epidemiology of IDDM in, 1632
factor V Leiden and coronary heart disease in, 198, 199
glucose tolerance in, homeostasis model assessment of, 673
insulin response in, criteria for fasting plasma glucose and, 1133
insulin sensitivity in, homeostasis model assessment of, 673
ketoacidosis-onset type 2 diabetes in, 1376, 1377
liver and kidney function in patients with maturity-onset diabetes of the young, 2144
and maturity-onset diabetes of the young, 2144
NIDDM
glucose tolerance and, insulin receptor substrate-1, codon 972 polymorphism in, 753
nephropathy in, 1080
smoking and serum leptin levels in type 2 diabetes, 516
type 2 diabetic patients, glomerular filtration rate in, link to atherosclerosis, 1848
Josimovich, John, B1

K

Ketoacidosis
as cause of meningeal syndrome, 1572
during gestational diabetes, 1031
enhanced subclinical coagulation activation during, 868

Ketoacidosis (continued)
GAD65 antibodies and, 2037
in IDDM children and adolescents, constant infused glucose regimen during recovery phase of, 676, 677
and onset of type 2 diabetes in Japanese, 1376, 1377
Ketonemia, B165
Ketonuria, B79, B132, B165
Kidney
function in Japanese patients with maturity-onset diabetes of the young, 2144
Kidney-pancreas transplantation
results reported at 1998 American Diabetes Association meeting, 2189
Koreans
type 2 diabetes, microalbuminuria in, 530
with NIDDM, retinopathy in, 134

L

Lactic acidosis
metformin and, 1364, 1366, 1587
intoxication and, 2036
rates in type 2 diabetes, 1659
Large-for-gestational-age (LGA) infants and gestational diabetes mellitus, B81, B83, B91, B101, B166
Laser irradiation, and skin circulation in microangiopathy, 580
Laser skin perforator, for determination of capillary blood glucose, 871
LDL cholesterol and troglitazone, 2201, 2202
LDL size distribution and insulin sensitivity, 2077
Left ventricular hypertrophy, ramipril and, in NIDDM, 804
Left ventricular wall motion
impairment in diabetic heart without coronary artery disease, 2123
Leptin
concentration, and troglitazone, in NIDDM, 1470
influence of sex differences in subcutaneous fat mass on, 1204
levels in type 2 diabetes, smoking and, 516
Leptinemia, and ischemic heart disease in men, 782
Leukocytes, polymorphonuclear, increased formation of hydrogen peroxide in, in IDDM patients, 326, 327
Levine, Rachmiel, tribute to, 1781
Lifestyle
intervention to prevent or delay diabetes onset, B46, B167
minority populations, culturally appropriate interventions in, 875, 876
modification with gestational diabetes mellitus, B121, B136
Lipid levels, effect of energy restriction and fat loss on, in obese type 2 patients, 695
Lipid metabolism
and fetal body composition, B99, B164
and glucose metabolism and cardiovascular risk factors, in adult Turner's syndrome, 1062
Lipid peroxides, relationship with thromboxane-B2, in type 1 diabetes, 1511
Lipids, metformin and, in insulin-treated NIDDM, 701
Lipoprotein, abnormalities, hyperglycemia and, as predictors of cardiovascular mortality in type 2 diabetes, 1861
Lipoprotein(a)
effect of insulin on, in new-onset IDDM, 866
glycemic control and, in type 1 diabetes, 1517
risk factor for coronary artery disease, in South Indian NIDDM patients, 1819
Lipoprotein lipase
intake of n-3 fatty acids and, in type 2 diabetic men, 717
and vascular endothelial damage in NIDDM patients with microalbuminuria, 2016
Lisinopril
albuminuria, exercise-induced, and, in IDDM, 1345
effect on progression to macroalbuminuria in IDDM, 104
Lispro. *See* Insulin lispro
Liver
function in Japanese patients with maturity-onset diabetes of the young, 2144
role in fetal development, B70
Low blood glucose index, and risk for severe hypoglycemia in IDDM, 1870
Low-density lipoprotein
coronary heart disease risk in NIDDM and, 1397
troglitazone and, in obese subjects, 796
Lymph node enlargement, autoimmune polyglandular syndrome and, 1573

M

Macroalbuminuria
and lisinopril in IDDM, 104
and nifedipine in IDDM, 104
and pentoxifylline, 2190
Macroangiopathy, in type 2 diabetes, 1451
Macrosomia, B2, B3, B4, B6, B7, B66, B80, B91, B100, B113, B134, B150
association with fetal hyperinsulinism, B60, B82–B83
association with gestational diabetes mellitus, B11, B12, B15, B34, B75, B95, B102, B164
association with maternal glycemia, B101
glucose monitoring and insulin therapy as means of avoiding, B134
and glucose tolerance test, B16, B33, B35, B39
glycemic control and early delivery as means of avoiding, B113–B116
Macrovascular complications, hyperglycemia and, 1167
Macrovascular disease, intensive insulin treatment and, 669
Maggot therapy, for foot ulcer treatment, 2030
Magnesium, supplementation with, in type 2 diabetes, 682, 2031
Malaysia, microalbuminuria in NIDDM in, 385
Malpractice, Physicians Insurers Association of America's database and, 1096
Malta, incidence of childhood type 1 diabetes in, 194
Maturity-onset diabetes of the young
liver and kidney function in Japanese patients, 2144
Managed care
elderly and, expenditure and use of services in, 747
peripheral neuropathy and, 1
role in management of gestational diabetes mellitus, B129
use of services by diabetic patients, 2062
using nurses and computer system to provide, 1037
value in reducing the burden and costs of diabetes treatment, C25
Management of diabetes care, electronic system for, impact on care of patients seen in subspecialty diabetes clinic, 972
Mastopathy, diabetic, 322
Meal dilution, glycemic response and, 711
Meals
high-carbohydrate, high-starch, metabolic response to in type 2 diabetes, 1619
moderate-carbohydrate, low-starch, metabolic response to in type 2 diabetes, 1619
Media, medicine and, 462
Medical nutrition therapy
effects of caloric restriction on weight loss and glycemic control in type 2 diabetes, 2
effects of monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors in type 2 diabetic patients, 9
Medical Research Council/British Heart Protection Study, 165
Medicare
and African-Americans, morbidity, quality of care, and resource utilization, 1090
diabetes care for beneficiaries of, 1282
therapeutic footwear benefit of, 777
Medicine, media and, 462
Men
ischemic heart disease in, leptinemia and, 782
nondiabetic, high blood glucose concentration as risk factor for mortality in, 360
older, hyperglycemia and risk of cardiovascular disease in, 1236
type 2 diabetes, intake of n-3 fatty acids and effect on glucose metabolism, 717
Meningeal syndrome, ketoacidosis as cause of, 1572
Menstrual irregularity, and type 2 diabetes in Pima Indians, 346
Metabolic alterations, in nondiabetic African-American women with history of gestational diabetes, 1250
Metabolic control, in IDDM adolescents, and quality-of-life self-assessment, 915
Metabolic syndrome
fibrinogen and, 649
association with lower heart rate variability, 2116
in postmenopausal women, birth weight, adult weight, girth as predictors of, 1652
Metabolism
effect of fetal metabolism on postnatal development, B142–B148
maternal, B142
and fetal growth, B85–B89
glucose metabolism and fetal growth, B72–B73, B99
placental, B75–B78
protein and nitrogen metabolism in pregnancy, B75–B78
Metagestational diabetes, B4
Metformin, B47
antihyperglycemic effect of, adipose tissue and, 1301
glycemic control and, in insulin-treated NIDDM, 701
glycogen synthase activity in obese patients

treated with, 1489
International Diabetes Federation Meeting and, 1024
intoxication, consequences of, 2036
lactic acidosis and, 1364, 1366, 1587
rates in type 2 diabetes and, 1659
lipoprotein(a) levels and, 2028
pseudohepatotoxicity of, 677
randomized trial of efficacy of in self-treated type 2 diabetes, effect on glycemic control, 87
serum lipids and, in insulin-treated NIDDM, 701
weight change and, effect on fibrinolysis and von Willebrand factor in obese nondiabetic subjects, 1967
Methionine synthase D919G mutation, in type 2 diabetes, relation to vascular events, 1774
Methylenetetrahydrofolate reductase gene, and NIDDM in Canadian Oji-Cree, 322
Metropolitan Diabetes Society of New York Meeting, 658
Mexican-Americans
early presentation of type 2 diabetes in, 80
genetic susceptibility to type 2 diabetes in, 80
retinopathy, risk of in type 2 diabetes, 1230
type 2 diabetes in, 80
Mexicans, children, IDDM incidence in, 1372
Micral-Test II test strip, microalbuminuria detection with, 878
Microalbuminuria
and carotid artery stiffness in IDDM, 99
detection of, with Micral-Test II test strip, 878
ethnic differences in correlates of, in NIDDM, 385
and hyperhomocysteinemia, 1028
incidence and determinants of, in type 2 diabetic Koreans, 530
in IDDM
hydroperoxides and intensified insulin treatment, 1295
in puberty, 1019
link of glomerular filtration rate to atherosclerosis in Japanese type 2 diabetic patients, 1848
in NIDDM
lipoprotein lipase and vascular endothelial damage and, 2016
predictors of progression to, 1932
and troglitazone, 2133
in type 1 diabetic children, blue-on-yellow and achromatic perimetry in, 2003
Microangiopathy
in type 2 diabetes, 1451
skin circulation in, laser irradiation and, 580
Microvascular complications
and adrenomedullin levels in type 1 diabetes, 999
cutaneous manifestations in IDDM and, 506
and nephropathy in hypertransfused patients with β-thalassemia, 1306
plasma homocysteine concentrations in type 1 diabetes and, 1843
Miglitol, and type 2 diabetes in African-Americans, 416
Minimal enteral feedings, B72
Minority populations, culturally appropriate lifestyle interventions in, 875, 876
Mitochondrial DNA, A-to-G mutation at nucleotide 8296 of, in Japanese, 2034
Monitoring, biological variation of glycated hemoglobin and, 261
Monocyte adhesion, gliclazide treatment and, in NIDDM, 487
Morbidity, in African-Americans on Medicare, 1090
Mortality
in adults with and without diabetes, in U.S. population, 1138
age of onset and prognosis of IDDM in Japanese children, 1674
all-cause, level of glycemia and, 1167
arrhythmia and, after myocardial infarction, 637
cardiovascular
level of glycemia and, 1167
in type 2 diabetes, predictors for, 1861
of diabetes in older adults, 231
impact of diabetes after first myocardial infarction, 69
risk of
from coronary and other causes in middle-aged Swedish men, 539
glycemic threshold for, 331
high blood glucose concentration and, in middle-aged nondiabetic men, 360
Motor nerve conduction velocity, ratio of, to F-wave conduction velocity in neuropathy, 615
Multiple Risk Factor Intervention Trial, 161
Muscular endurance, in long-term IDDM patients, 597
Myocardial infarction
arrhythmia and mortality after, 637
diagnosis of preexisting diabetes and, 461
impact of diabetes on mortality following, 69
in type 2
Afro-Caribbeans, 1271
Caucasians, 1271
South Asians, 1271
postmenopausal estrogens and, 1117

N

National Center for Disease Statistics
and growth in children and adolescents, B146
National Center for Health Statistics, B144
National Cholesterol Education Program, 166
National Diabetes Data Group, B2, B5, B14, B33, B34, B50, B100, B144, B161
modification of O'Sullivan–Mahan criteria, B33, B34
standard for threshold values, B40
National Diabetes Education Program, C30
National Health and Nutrition Examination Survey, Epidemiologic Follow-up Study, 1828
National Institute of Child Health and Human Development-Diabetes in Early Pregnancy Study, B135
Neonatal hypoglycemia, B6
Nephropathy
American Diabetes Association Annual Meeting and, 315
American Diabetes Association position statement, S50
association of exercise capacity with complications in NIDDM, 291
clinical evaluation of, 97
Diabetes Control and Complications Trial, nonimplementation in high-risk patients, 1367
diagnosis of, proteinuria and, 1076
in elderly Japanese NIDDM patients, 111
endothelial dysfunction and, in IDDM, 841
foot care, S54
glomerular charge and size selectivity, assessed by changes in salt intake in type 2 diabetes, 482
hyperhomocysteinemia and, in IDDM, 841
in hypertransfused patients with β-thalassemia, 1306
incidence of, in early-onset Japanese NIDDM patients, 1080
increased left ventricular mass in type 1 diabetes, 1534
International Diabetes Federation Meeting on, 1560
lisinopril's effect on progression to macroalbuminuria in IDDM, 104
nifedipine's effect on progression to macroalbuminuria in IDDM, 104
proteinuria in screening and diagnosis of, 1076
screening for, proteinuria and, 1076
Teczem Consultant Meeting and, 315
test for determination of urinary albumin-to-creatinine ratio and, 97
in type 2 diabetic Brazilian patients, familial history of arterial hypertension, coronary heart disease, renal disease in, 1545
in type 2 diabetic Koreans, microalbuminuria and, 530
Netherlands, seasonality of birth in childhood diabetes in, 190
Neuropathy
American Diabetes Association meeting and, 183, 2023
amputation and
lower-limb, in community, 738
peripheral arterial occlusive disease as determinant for, 625
autonomic, effects on counterregulation and awareness of hypoglycemia in type 1 diabetes, 1960
cost of inpatient care, 42
defective nerve conduction, reversal of with vitamin E supplementation in type 2 diabetes, 1915
Diabetes Control and Complications Trial, nonimplementation in high-risk patients, 1367
diabetic peripheral sensorimotor polyneuropathy, glycemic control and, 1749
distortion-product otoacoustic emissions and selective sensorineural loss in IDDM, 1317
dynamic forces transmitted through foot in, 1955
epidemiology, 42
foot skin microcirculation, 1339
foot ulceration
becaplermin and, 822
incidence of and risk factors for, multicenter study of, 1071
peripheral arterial occlusive disease as determinant for amputation in, 625
power spectral analysis of heart rate variation in patients with, 1173
forearm skin microcirculation, 1339
International Diabetes Federation meeting on, 1198
microangiopathy, skin circulation in, laser irradiation and, 580

Neuropathy (continued)
and muscular endurance in long-term IDDM patients, 597
peripheral
amitriptyline for symptomatic relief of, 1322
electrotherapy for symptomatic relief of, 1322
testing for, 1, 23
plasma homocysteine concentrations in type 1 diabetes and, 1843
and progression to microalbuminuria in NIDDM, 1932
ratio of motor nerve conduction velocity to F-wave conduction velocity in, 615
sympathetic function test of vasoconstrictor changes in foot arteries, 1495
Neuropsychological complications, in IDDM children two years after onset, 379
NIDDM, B9, B11, B43, B47, B140. *See also* Diabetes *and* Type 2 diabetes
acarbose in patients with poor control on conventional oral agents, 1154
acutely decompensated, insulin lispro compared with human regular insulin, after interruption of continuous subcutaneous insulin infusion in, 817
and advanced glycation end products, increased levels of, 1027
in African-Americans, physical activity and, 555
amylin and amylin-like peptide concentrations and response to sulfonylurea or insulin therapy in, 810
β_3-adrenergic receptor, genetic variation of, and metabolic phenotypes in Oji-Cree, 851
in Canadian Oji-Cree
factor V Leiden and vascular disease in, 1203
methylenetetrahydrofolate reductase gene, dietary folate, and atherosclerosis in, 322
carotid arterial intimal-medial thickening, and plaque formation in, 323, 324
carvedilol and endothelium-dependent vascular functions in, 631
compared with gestational diabetes mellitus, B11, B13, B23–B24, B44
coronary heart disease risk in, low-density lipoprotein and, 1397
in elderly
cifenline succinate and dementia in, 320
GAD antibodies in, 675
Japanese patients, glycemic control and blood pressure in development and progression of nephropathy in, 111
endothelial function in, 271
epidemiology of, B150, B154
E-selectin, and vascular cell adhesion molecule-1 in, 1008
ethnicity and microalbuminuria in, 385
fatty acid-binding protein 2 gene and coronary heart disease in, 849
genetic predisposition toward, in offspring of South Indian NIDDM parents, 76
gliclazide treatment in, 487
glomerular filtration rate in, estimating from plasma creatinine concentration after cimetidine administration, 216
glucose tolerance and, insulin receptor substrate-1, codon 972 polymorphism in, 753
glycemic control and glucose counterregulation during hypoglycemia during, 1330
and hearing loss, 1540
in Hispanics, α-glucosidase inhibition in, 409
hypercholesterolemia in
gemfibrozil and, 477
simvastatin and, 477
hyperlipidemia in
gemfibrozil and, 477
simvastatin and, 477
hypertension and
perindopril and carvedilol effects on endothelium-dependent vascular functions in, 631
Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial, 597, 655
and impaired β-cell function, B151
influence of gender, autoantibodies, and obesity on diabetes in patients aged 40–75 years in, 250
insulin resistance, 62
as common factor with gestational diabetes mellitus, B27
stiffness indexes β of carotid and femoral arteries, 1178
insulin sensitivity in, resistance training and, 1353
insulin-treated, metformin's effect on glycemic control and serum lipid levels in, 701
in Japanese
and Asp905Tyr polymorphism of gene for skeletal muscle-specific glycogen-targeting subunit of protein phosphatase 1, 1086
nephropathy and, 1080
in Koreans, retinopathy and, 134
lactic acidosis and metformin in, 1366
lean
platelet sensitivity to insulin in, 121
platelet sensitivity to nitrates in, 121
lipoprotein lipase and vascular endothelial damage in, 2016
mapping genes for, 949
metformin and lactic acidosis in, 1366
microalbuminuria in
ethnic differences in correlates of, 385
predictors of progression to, 1932
and mutations in HFE, 1371
National Diabetes Data Group criteria and prognosis in women with prior gestational diabetes mellitus, B50
obesity in
glycemic response to diet restriction and weight loss in, 687
irreversibility of defect in glycogen synthase activity from, 1489
platelet resistance to nitrates in, 121
perindopril and endothelium-dependent vascular functions in, 631
physical activity in, effectiveness of community-based approach to, 195
plasma leptin concentration, and troglitazone in, 1470
possible confusion with gestational diabetes mellitus, B120
in postmenopausal women, lower-body fat and, 828
prevention, alpha-glucosidase inhibitor and, 1720
prevention of late onset in women with gestational diabetes mellitus, B12, B20, B22, B43, B50
ramipril and left ventricular hypertrophy in, 804
resistance training and insulin sensitivity in, 1353
risk of, γ-glutamyltransferase and, 732
risk in children of women with gestational diabetes mellitus, B79, B140
risk factors in those with gestational diabetes mellitus, B19, B43–B47, B50–B55, B161
diet, B46
glucose intolerance, B161
hormones, excessive intake of, B45, B51–B54, B51, B58
hyperglycemia, B50, B70
impaired β-cell function, B161
obesity, B45, B50, B161
serum ferritin and, 62
serum 1,5-anhydroglucitol and urinary excretion of N-acetyl glucosaminidase and albumin and, 619
in South Indians
foot pressure measurement in, 1205
risk factors for coronary artery disease and, 1819
and suboptimal fetal growth, B150–B154
"thrifty phenotype" hypothesis, B154
troglitazone, and plasma leptin concentration in, 1470
vascular endothelial damage and lipoprotein lipase in, 2016
voglibose and
effects on glycemic excursions, insulin secretion, insulin sensitivity in, 256
glycemic excursions in, 1206
Nifedipine, effect on progression to macroalbuminuria in IDDM, 104
Nigerians
hypertension risk in, and type 2 diabetes, 1836
waist circumference of, and type 2 diabetes, 1836
Nitrogen metabolism, B75–B76, B78
effect of gestational diabetes mellitus, B76
Nitrotyrosine, in diabetic placenta, 1753
Norepinephrine
effect of maternal diabetes, B157
in fetal development, B156–B157
Nuclear factor-κB binding activity in peripheral blood mononuclear cells, and glycemic control in type 1 diabetes, 1310
Nutrition
and β-cell impairment, B132, B152
in extremely low birth weight (ELBW) infants, B71
and fetal growth restriction, B71, B153–B154
food labeling, S62
perinatal, B70, B96, B101, B119, B124–B125, B164
postnatal, B71
protein intake, B131
Nutrition recommendations
for health care institutions, American Diabetes Association position statement, S66

for people with diabetes mellitus, American Diabetes Association position statement, S32
Nutrition therapy
fat replacers in, S64
in type 1 diabetes, 658
Nutritional counseling
as treatment for gestational diabetes mellitus, B1

O

Obesity
adult, B21
android type, correlations of tumor necrosis factor-alpha and endothelin 1 levels with C-peptide concentration in, 1778
childhood
and gestational diabetes mellitus, B6, B34, B138, B139–B140, B142, B145–B146, B148
effects of monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors in type 2 diabetic patients, 9
γ-glutamyltransferase and NIDDM risk in, 732
and geographic location, B94
and gestational diabetes mellitus, B6, B138, B140, B167
glycemic response to diet restriction and weight loss, in NIDDM, 687
in elderly type 2 diabetic patients, physiological importance of first-phase insulin release in, 1326
and impaired glucose tolerance in Alaskan Eskimo, 563
influence on diabetes in patients aged 40-75 years, 250
and insulin lispro and glycemic control, in patient with insulin-requiring type 2 diabetes, 1575
insulin treatment of, 1052
with evening 70/30 insulin plus glimepiride, 1052
lifestyle intervention in, where family history of diabetes, 350
and NIDDM, B150, B151
irreversibility of defect in glycogen synthase activity from, 1489
orlistat and, in type 2 diabetes, 1288
and pregnancy, B134
and prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults, 518
reducing body weight and conversion to overt diabetes, 334
risk in children of women with gestational diabetes mellitus, B79, B145–B146, B161
as risk factor for postpartum NIDDM, B45, B50
screening for diabetes in, 468
troglitazone and LDL proportion and resistance to oxidation in, 796
in type 2 diabetes, 1680
association with blood pressure, 111
association with fasting plasma glucose, 111
effect on lipid levels of energy restriction and fat loss, 695
weight change and metformin in, effect on fibrinolysis and von Willebrand factor, 1967
weight gain and risk of developing insulin resistance syndrome, 1637
Obstetrical Society of London, B6
Obstetric history, B11, B166
1,5-anhydroglucitol and urinary excretion of *N*-acetyl glucosaminidase and albumin and, in NIDDM, 619
100-g 3-h oral glucose tolerance test, B1, B5, B15, B33–B41, B161, B162
and higher fasting glucose levels, B135
and morbidity in pregnancy, B33–B41
Oral glucose tolerance test, B94, B100, B167
abnormality thresholds, B14–B16
and assessment of insulin secretion in normal glucose-tolerant relatives of type 2 diabetic subjects, 278
and cystic fibrosis–related diabetes, 2199
Diabetic Pregnancy Study Group criteria, B6
50-g 1-h test, B14–B15, B33
Fourth International Workshop-Conference on Gestational Diabetes Mellitus criteria, B161
and gestational diabetes mellitus–associated hypertension, B29
and incidence of large-for-gestational-age infants, B101
and neonatal morbidity, B82
100-g 3-h test, B1, B5, B15, B33–B41, B161, B162
alternatives to, B16
and Carpenter and Coustan criteria for gestational diabetes mellitus, B101
and Langer et al. diagnostic criteria for gestational diabetes mellitus, B101
and pregnancy outcome, B39
75-g 2-h test, B6, B12, B15–B16, B43, B138, B161, B163
Diabetic Pregnancy Study Group, B6
in study of Pima Indians, B16, B138–B139
World Health Organization criteria, B6
Orlistat, and obese type 2 diabetic patients, 1288
O'Sullivan-Mahan criteria, B1, B5, B33, B34, B39, B161, B163
first to propose glucose challenge test, B33
National Diabetes Data Group revision of, B5–B6, B33
predictive value for future diabetes in mother, B6
predictive value for gestational diabetes mellitus, B6, B58
Oxford Record Linkage Study, 42
Oxford Database on Effective Care in Pregnancy and Childbirth
screening recommendations, B15
Oxidative stress
meal-generated, in type 2 diabetes, 1529
and nephropathy in hypertransfused patients with β-thalassemia, 1306
nitrotyrosine in diabetic placenta, 1753
and thromboxane-B_2 in type 1 diabetes, 1511
in type 1 children and adolescents, at onset and in early stages, 1736
in young type 1 patients, puberty and, 1990

P

Pancreas
implantable artificial, 444
transplantation
American Diabetes Association position statement, S79
hypoglycemia after, 1944
kidney-pancreas, results reported at 1998 American Diabetes Association meeting, 2189
Pancreatic β-cell(s)
in Caucasians, 127
fetal
apoptosis and ontogeny, B63
hyperplasia, B60
maturation, B64
renewal, B62
insulin therapy and, in NIDDM, 810
maternal
as risk factor for progression from gestational diabetes mellitus to NIDDM, B50
impaired function, B20, B132, B151–B152
in pregnant women with normal and abnormal glucose tolerance, 403
in South Asians, 127
in South Indians, 76
in Pima Indians, 127
sulfonylurea and, in NIDDM, 810
in thiamine-responsive megaloblastic anemia, 38
Pancreatic β-cell rest, induction of, in type 1 diabetes, 427
Pape, Frederica, B3
Paris Prospective Study, 360
Parity
association with diabetes, B51
association with gestational diabetes mellitus, B45
Pederson, Jorgen, B4, B99
Pediatric diabetes care, emergency telephone hotline service and, 1365
Pediatric-onset type 2 diabetes, 80
Pentoxifylline
and macroalbuminuria, 2190
Peptide growth factors
association with gestational diabetes mellitus, B60
effect on islet cell maturation, B64
Perinatal morbidity and mortality
association with gestational diabetes mellitus, B34, B43, B80–B81, B91, B113, B118
association with maternal glycemia, B101
Perindopril, and endothelium-dependent vascular functions, in NIDDM with hypertension, 631
Peripheral arterial occlusive disease, as determinant for amputation in subjects with foot ulcers, 625
Peripheral vascular disease
cost of inpatient care for, 42
epidemiology of, 42
Phlebotomy
and plasma glucose and insulin, 2190
Physical activity
coronary artery bypass and, 1603
effectiveness in NIDDM, community-based approach, 195
and NIDDM in African-Americans, 555
Physicians Insurers Association of America, use of database as surveillance tool for malpractice claims, 1096
Pima Indians
hyperinsulinemia in, 127
insulin secretion in, 127
long-term effects of gestational diabetes mellitus on children of, B138–B140
pancreatic β-cell function in, 127
type 2 diabetes, menstrual irregularity and, 346

Pitt County Study, 555
Placenta
role in fetal development, B70
transport, B100
Plaque formation, and carotid arterial intimal-medial thickening, in NIDDM, 323, 324
Plasma lipid peroxides, normalization of, gliclazide treatment and, in NIDDM, 487
Plasma pancreastatin-like levels, increased, in gestational diabetes, 1951
Plasmapheresis, insulin resistance, type B syndrome and, 1217
Plasminogen activator inhibitor 1, variation in promoter (4G/5G) in, in type 2 diabetes, 463
Platelet resistance
to nitrates in obese NIDDM, 121
to nitrates in obesity, 121
Platelet sensitivity
to insulin, in lean NIDDM, 121
to nitrates, in lean NIDDM, 121
Polyol-pathway metabolites, influenced by aldose reductase content in erythrocytes, 1014
Postprandial glycemic response, meal dilution and, 711
Pramlintide, and metabolic profile of insulin-treated type 2 diabetic patients, 987
Prediabetes in pregnancy, B4
Preeclampsia and eclampsia, B11, B12, B27, B29, B32, B34, B39, B79, B166
Pregnancy and perinatal complications, B79, B118
in diabetes, B29
diabetes in early, 1978
diabetic
nitrotyrosine in placenta, 1753
pre-conception planning, 887, 889
gestational diabetes mellitus, B29, B127, S60
and amylin increase, 668
ketoacidosis during, 1031
glucose intolerance in, effects on newborn outcomes, 871
glucose tolerance test, 75-g, 1807
and glycemic control in IDDM, 374
glycemic control in pre-conception period and early, effect on birth weight, in women with IDDM, 535
IDDM, fetal growth and counterregulatory responses to hypoglycemia in, 199, 200
and pancreatic β-cell function in women with normal and abnormal glucose tolerance, 403
preconception care
American Diabetes Association position statement, S56
Pregnancy outcome
association with carbohydrate metabolism, B37
association with oral glucose tolerance test, B39
cost-benefit analysis, B129
in gestational diabetes mellitus, B58, B115, B128, B165–B166
in gestational diabetes mellitus and hypertension in pregnancy, B31, B166
Prescription drug use and costs, among diabetic patients in Germany, 389
Prevention, of type 1 diabetes, S83
Primary care physicians
attitudes and behaviors of
with Medicare beneficiaries, 1282
toward diabetes, 1391
Proinsulin
des 31,32, in populations at risk for type 2 diabetes, 127
in populations at risk for type 2 diabetes, 127
Protein, ingestion and insulin secretion, 16
Protein phosphatase 1, Asp905Tyr
polymorphism of gene for skeletal muscle-specific glycogen-targeting subunit of, in NIDDM in Japanese, 1086
Proteinuria, and nephropathy, screening and diagnosis of, 1076
Pseudopseudohypoparathyroidism, in type 2 diabetes, 1575
Psychomotor development in children of mothers with gestational diabetes mellitus, B143, B145
Psychosocial adaptation, to diabetes, family environment and, 241
Puberty
and childhood IDDM in Japan, 1674
endothelial dysfunction and, in young type 1 patients, 1990
and growth in IDDM, determined by HbA_{1c} levels, sex, bone age, 831
IDDM in, albumin excretion and, 1019
oxidative stress and, in young type 1 patients, 1990
Puerto Rico, children in, IDDM incidence in, 744

Q

Qualitative research in diabetes, 1387
Quality of care
in African-Americans on Medicare, 1090
American Diabetes Association meeting on, 457
Quality of life
in adolescents, intensive diabetes management protocols and, 885
determinants of, intensified insulin therapy and, 1876
diabetes-specific scale for type 1 patients, 757
domperidone, effect of, in patients with symptoms of diabetic gastroparesis, 1699
and glycemic control in type 2 diabetes, C44
in IDDM adolescents
metabolic control and, 915
personal and family factors associated with, 909
insulin lispro and, 1203
model to estimate impact of type 1 diabetes on, 725
Quebec Cardiovascular Study, 782

R

Ramipril, and left ventricular hypertrophy, in NIDDM, 804
Rancho Bernardo Study, 1236, 1652
Recombinant human platelet-derived growth factor-BB, and foot ulceration, efficacy and safety of, 822
Redux state, influenced by aldose reductase content in erythrocytes, 1014
Renal disease
familial history of, in Brazilian type 2 diabetic patients with nephropathy, 1545
glomerular filtration rate in NIDDM and, estimating from plasma creatinine concentration after cimetidine administration, 216
Renal failure
and nephropathy in early-onset Japanese NIDDM patients, 1080
Renal function
apolipoprotein E polymorphism and, in Germans, 994
lactic acidosis and metformin in, 1366
in NIDDM, 619
Repaglinide, randomized placebo-controlled trial of, in type 2 diabetes, 1897
Resistance training, insulin sensitivity and, in NIDDM, 1353
Respiratory distress syndrome, B91
Retinopathy, 143
American Diabetes Association position statement, 157, S47
association of exercise capacity with complications in NIDDM, 291
association with fibroblast growth factor levels, B66
in Caucasians, non-Hispanic, with type 2 diabetes, 53
comments on position statements on, 1378, 1379
Diabetes Control and Complications Trial, nonimplementation in high-risk patients, 1367
general practitioners and information to patients regarding, 324
hepatocyte growth factor and, 1759
in Hispanic-Americans with type 2 diabetes, 53
International Diabetes Federation Meeting on, 1560
in Koreans with NIDDM, 134
microalbuminuria and, 530
prevalence, glucose tolerance and, 1664
proliferative diabetic, development of in type 1 African-Americans and whites, 792
risk of
in Mexican-Americans with type 2 diabetes, 1230
in non-Hispanic blacks with type 2 diabetes, 1230
in non-Hispanic whites with type 2 diabetes, 1230
self-rated health and diabetes of long duration and, 236
sight-threatening, and improved visual function in IDDM, 2007
Rifkin, Harold, 320
Rigiscan, and evaluation of erectile disorders, 1159
Risk assessment, in relatives of type 1 diabetic patients, islet autoantibody screening for, 1445
Risk factors
BMI, in black and white Americans, 1828
cutaneous manifestations in IDDM, association with, 506
for type 2 diabetes, C3

S

San Antonio Heart Study, 163, 1167
San Luis Valley Diabetes Study, 53
Santiago, Julio, tribute to, 320
Sardinia, IDDM in, seasonal pattern in clinical onset of, 1101
Scandinavian Simvastatin Survival Study, 164
Screening
American Diabetes Association risk test in community program for, 1029, 1030
biological variation of glycated hemoglobin

and, 261
criteria
age, B14, B33, B44
diet, B46
exercise, B46
family history, B45
fasting plasma insulin, B20
obesity, B45
parity, B45
proinsulin levels, B20
in obesity, 468
for type 2 diabetes, S20
recommendations
American College of Obstetricians and Gynecologists, B15
American Diabetes Association, B15
universal versus selective, B58, B162
Self-management education
national standards for, S95
third-party reimbursement for, S86
Self-monitoring of blood glucose
development of a scale to measure adherence to, 1046
finger infection and, 1373
meters, clinical and statistical evaluation of, 1919
Serum ferritin, and insulin resistance syndrome, 62
75-g 2-h oral glucose tolerance test, B6, B12, B16, B43, B161, B163
Diabetic Pregnancy Study Group, B6
in study of Pima Indians, B138–B139
World Health Organization criteria, B6
Sex, as determinant of pubertal growth in IDDM, 831
Shoulder dystocia, B7, B114–B116
Sickle cell trait, effects of, on determinations of HbA_{1c} by immunoassay, 983
Simvastatin
hypercholesterolemia and, in NIDDM, 477
hyperlipidemia and, in NIDDM, 477
Skaraborg Diabetes Registry, 546
Skin circulation, in microangiopathy, laser irradiation and, 580
Smoking
assessment of by urinary cotinine measurements in type 1 adolescents and young adults, 787
and glycemic control in NIDDM, 1932
and risk of mortality in middle-aged Swedish men, 539
serum leptin levels in, type 2 diabetes and, 516
Somogyi-Nelson technique, B2
Sorbitol concentrations, erythrocyte, measuring in patients with diabetic complications and treated with aldose reductase inhibitor, 672
South Asians
hyperinsulinemia in, 127
insulin secretion in, 127
NIDDM, foot pressure measurement in, 1205
pancreatic β-cell function in, 76, 127
study of genetic prediabetic, 76
type 2 diabetes, myocardial infarction in, 1271
St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention Study, 641
Standards of care for diabetes mellitus
American Diabetes Association position statement, S23
Stillbirth, association with gestational diabetes mellitus, B11, B12
STOP-NIDDM Trial, 1720
Strong Heart Study, 1258
Study to Prevent NIDDM, 1720
Sulfonylurea(s)
amylin and amylin-like peptide concentrations and, in NIDDM, 810
International Diabetes Federation meeting and, 1024
with troglitazone, and glycemic control in type 2 diabetes, 1462
Surveillance system, use in managed care of diabetic patients, 2062
Sweating response, studies in fetal development, B157
Sweden
diabetes prevalence in, 546
influence of gender, autoantibodies, and obesity on diabetes in patients aged 40-75 years in, 250
men, risk of mortality from coronary and other causes in middle-aged, 539
Sympathetic nervous system
effect of temperature, B158
fetal development, B156–B160
and norepinephrine, B156

T

Taiwanese, screening for diabetes, fasting plasma glucose and, 1856
Teczem Consultant Meeting, 315
Temperature, effect on fetal development, B157–B158
Thalassemia major, diagnosis of diabetes in, 671
Therapeutic interventions, B46–B47
Therapies, unproven, S85
Thiamine-responsive megaloblastic anemia, 38
Third National Health and Nutrition Examination Survey, 1988-1994, 518
Third-party reimbursement, for diabetes care, self-management education, supplies
American Diabetes Association position statement, S86
Thromboxane-B_2
relationship with lipid peroxides, in type 1 diabetes, 1511
and vitamin E, effect on lipid peroxide levels in type 1 diabetes, 1511
Tolbutamide, B46
Toronto Tri-Hospital Gestational Diabetes Project, B7, B33–B41, B100, B116
Transient hypoglycemic hemiparesis, in IDDM children, 1567
Transplantation, of pancreas, hypoglycemia after, 1944
Treatment of gestational diabetes mellitus
evaluation criteria, B92, B163
recommendations
of the American College of Obstetricians and Gynecologists, B94
of the Third International Workshop-Conference on Gestational Diabetes Mellitus, B94, B101, B118
Troglitazone, B47
and fulminant hepatitis, 2140
gemfibrozil and, 2028
International Diabetes Federation Meeting and, 1024
and LDL cholesterol, 2201, 2202
LDL proportion and resistance to oxidation, in obese subjects, 796
learning to use, 1389
and microalbuminuria, 2133
and plasma leptin concentration, in NIDDM, 1470
with sulfonylurea, and glycemic control in type 2 diabetes, 1462
in type 2 diabetic patients, insulin-treated, 1455
Tumor necrosis factor-α, B23
endothelin 1 levels and, correlation with increased C-peptide concentration in android type obesity, 1778
production, gliclazide treatment and, in NIDDM, 487
Turner's syndrome, glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult, 1062
Type 1 diabetes
adolescent
advanced glycation end product, N^{ϵ}(carboxymethyl)lysine and, 1997
oxidative stress at onset and in early stages of, 1736
smoking and, 787
adrenomedullin levels in, 999
in African-Americans, retinopathy and, 792
in aged, transferring from human to animal insulin in, 196
amylin and, 664
apolipoprotein E polymorphism and renal function in Germans with, 994
attentional functioning in, severe hypoglycemia and, 1568
β-adrenergic sensitivity in, 1939
hypoglycemia and, 1505
in Caucasians, retinopathy and, 792
childhood
advanced glycation end product, N^{ϵ}(carboxymethyl)lysine and, 1997
blue-on-yellow and achromatic perimetry in, 2003
incidence of in Malta, 194
oxidative stress at onset and in early stages of, 1736
community nursing service and dependency in, 1567
continuous subcutaneous insulin infusion, effect on hepatic responsiveness to glucagon in type 1 diabetes, 1627
coronary artery disease in, and family history of type 2 diabetes, 610
etiology, 2185
exercise, glycemic control during, 1775
GAD antibodies, at birth in children with, 197
genetic heterogeneity of, 658
glucose monitoring in, 661
glycemic control in, 1517
blood glucose meters with storage capability and computer-assisted analyses and, 1694
during exercise, 1775
insulin aspart and, 1904
nuclear factor-κB binding activity in peripheral blood mononuclear cells in, 1310
homocysteine concentrations in, 1843
hypoglycemia in, 660
awareness of and effects of autonomic neuropathy in, 1960
and β-adrenergic sensitivity in, 1505
effect of insulin lispro on, 1726
increased left ventricular mass in, 1534
induction of β-cell rest in, 427

Type 1 diabetes (continued)
IGF treatment in, 664
immune therapy versus nutritional therapy in, 658
insulin aspart and glycemic control in, 1904
insulin lispro
and daytime NPH insulin in, 1707
blood glucose control in, 32
effect on hypoglycemia, 1726
postprandial, in, 570
insulin treatment in, 662
interferon-α and development of, 1774
International Diabetes Federation meeting and, 658
islet transplantation in, 663
lipid peroxides and thromboxane-B_2 in, 1511
lipoprotein(a) in, 1517
Metropolitan Diabetes Society of New York meeting and, 658
neuropathy and, effects of, 1960
nutritional therapy versus immune therapy in, 658
in pregnancy, β-hydroxybutyrate levels in, 1978
prevention
American Diabetes Association position statement, S83
quality of life and
model to estimate impact of, 725
scale for patients with, 757
relatives of patients with, islet autoantibody screening for risk assessment for, 1445
self-monitoring of blood glucose in, 461
thromboxane-B_2, and lipid peroxides in, 1511
vitamin E and, effect on thromboxane-B_2 and lipid peroxide levels in, 1511
in young adults, smoking and, 787
in young patients
ACE gene polymorphism as risk factor for carotid artery intima-media thickening in, 836
endothelial dysfunction, and, 1990
oxidative stress and, 1990
Type 2 diabetes
acarbose, safety and efficacy, 2050, 2056
in African-Americans
with α-glucosidase inhibition, chronic treatment of, 416
and albuminuria in, 1576
and albuminuria in African-Americans, 1576
apolipoprotein E polymorphism and renal function in Germans with, 994
biological variation of glycated hemoglobin and, 261
in Brazilians, familial history of arterial hypertension, coronary heart disease, renal disease in, 1545
caloric restriction and, effect on weight loss and glycemic control in, 2
carbohydrate intake and acarbose, effect on HbA_{1c} and gastrointestinal symptoms in, 1612
cardiovascular disease
and ethnicity in, 1271
outcomes in, 641
cardiovascular mortality in, 1861
in Chinese, 1035
albuminuria in, angiotensinogen T235 and ACE insertion/deletion polymorphisms and, 431
complications
costs of, 1122
and glycemic control, C39
cost-effectiveness of treatment of, 464
defective nerve conduction in, reversal of with vitamin E supplementation, 1915
determining glomerular filtration status in newly presenting, 1893
dissociation of microangiopathy and macroangiopathy in, 1451
early presentation in Mexican-American youth, 80
effects of monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors in obese patients, 9
and endotheliopathy, 2047
ethnicity and cardiovascular disease in, 1271
family history of, association with coronary artery disease in type 1 diabetes, 610
fasting glycemia in, influence of glucagon-like peptide 1 on, 1925
and first-phase insulin release, physiological importance of in elderly, 1326
fractional esterification rate of HDL particles in, 139
genetic susceptibility, in Mexican-American youth, 80
glipizide and insulin in, 574
glomerular charge and size selectivity, assessed by changes in salt intake in, 482
glucose tolerance
and carotid wall thickness in, 1812
in rural native Hawaiians, 549
glycemic control
and hypoglycemia in, 283
and quality of life, C44
with troglitazone and sulfonylurea, 1462
in Hispanics, diabetes education curriculum and, 896
hormone replacement therapy and carotid wall thickness in women with, 1790
hyperglycemia in, 1525
hypertension risk and, in Nigerians, Jamaicans, and African-Americans, 1836
hypoglycemia and glycemic control in, 283
implantable insulin pump and, 1596
insulin and glipizide in, 574
insulin-requiring, insulin lispro and glycemic control in, 1575
insulin secretion in, stimulation of by fructose, 16
insulin therapy in, well-being and symptoms in relation to, 919
insulin-treated, pramlintide and metabolic profile of, 987
insulin treatment in obesity and, with evening 70/30 insulin plus glimepiride versus insulin alone, 1052
International Diabetes Federation meeting and, 860
in Japanese
glomerular filtration rate and atherosclerosis in Japanese patients, 1848
ketoacidosis-onset, 1376, 1377
in Koreans, microalbuminuria in, 530
lactic acidosis rates in, 1659
magnesium supplementation in, 682, 2031
in men, intake of n-3 fatty acids and effect on glucose metabolism, 717
metabolic response to high-carbohydrate, high-starch meals in, 1619
metformin
antihyperglycemic effect of and role of adipose tissue in, 1301
randomized trial of efficacy of in self-treated, 87
methionine synthase D919G mutation and, relation to vascular events, 1774
obesity and, 1680
effect on lipid levels of energy restriction and fat loss, 695
insulin treatment in, 1052
orlistat in treatment of, 1288
oxidative stress, meal-generated, in, 1529
pediatric-onset, 80
peripheral neuropathy in, electrotherapy and amitriptyline in symptomatic relief of, 1322
in Pima Indians, menstrual irregularity and, 346
plasminogen activator inhibitor 1, variation in promoter (4G/5G) in, 463
prevalence in elderly, 959
prevention, alpha-glucosidase inhibitor and, 1720
progression to, in high-risk groups in China, 1183
proinsulin use in populations at risk for, 127
pseudopseudohypoparathyroidism, 1575
relatives of patients with, insulin secretion in, 278
repaglinide and, 1897
retinopathy in, 53
risk of, 1230
reversion to nondiabetic status, 1266
risk factors, C3
screening for
American Diabetes Association position statement, S20
serum ceruloplasmin in, 1525
severity of
associated with fasting plasma glucose, 111
associated with obesity, 111
association with blood pressure, 111
single-kidney status in, urinary albumin excretion rate and glomerular filtration rate in, 1521
smoking and serum leptin levels in, 516
sulfonylurea secondary failure, influence of glucagon-like peptide 1 one fasting glycemia in, 1925
symptoms of, 111
treatment issues, International Diabetes Federation meeting and, 1024
troglitazone and, 1389
in insulin-treated, 1455
vitamin E supplementation and reversal of defective nerve conduction in, 1915
waist circumference and, in Nigerians, Jamaicans, and African-Americans, 1836

U

U.K. Prospective Diabetes Study, 32, 87, 111, 1271, C35
American Diabetes Association position statement, 2180
Ulceration
cost of inpatient care for, 42
epidemiology of, 42
and lower extremity amputation, 42
United States
adults, prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in, 518
economic consequences of diabetes in, 296, C11

type 2 diabetes in, and costs of complications, 1122
U.S. Preventive Services Task Force, B5
Uremia, and HbA_{1c}, measured by high-performance liquid chromatography, 463
Urinary albumin excretion rate, and glomerular filtration rate, in single-kidney type 2 diabetic patients, 1521
Urinary albumin-to-creatinine ratio
clinical evaluation of, 97
test for determination, 97
Urinary cotinine measurement, as assessment of smoking in type 1 adolescents and young adults, 787

V

Vanadyl sulfate and insulin action, 2194
Vascular cell adhesion molecule-1, E-selectin and, in NIDDM, 1008
Vascular disease
factor V Leiden and, in Canadian Oji-Cree, 1203
plasma homocysteine concentrations in type 1 diabetes and, 1843
Vascular endothelial damage, lipoprotein lipase and, in NIDDM patients with microalbuminuria, 2016
Vascular events, in type 2 diabetes, 1774
Vascular complications
and Glu^{298}→Asp (894G→T) mutation, 2195
Vasodilatation
endothelium-dependent, impairment in women with previous gestational diabetes, 2111
Ventricular mass, increased left, in type 1 diabetic patients with nephropathy, 1534
Veterans Affairs Cooperative Study in Type 2 Diabetes Mellitus, 510
Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 diabetes, 574
Veterans Affairs Implantable Insulin Pump Study, 1596
Veterans Health Administration
ambulatory care pharmacy-derived database of, 368
diabetes prevalence and hospital and pharmacy use in, 368
Vitamin E
effect on thromboxane-B_2 and lipid peroxide levels in type 1 diabetes, 1511
and reversal of defective nerve conduction in type 2 diabetes, 1915
Voglibose
effect on serum 1,5-anhydroglucitol concentrations, 465
and glycemic excursions and, in NIDDM, 256, 1206
and insulin secretion, in NIDDM, 256
and insulin sensitivity, in NIDDM, 256
von Willebrand factor
lipoprotein lipase and vascular endothelial damage in NIDDM, 2016
weight change and metformin, effect on, 1967
Vulvovaginal candidiasis, treatment of, 451

W

Waist circumference, hypertension and, and type 2 diabetes in Nigerians, Jamaicans, and African-Americans, 1836
Weight, adult, as predictor of metabolic syndrome in postmenopausal women, 1652
Weight change, metformin and, effect on fibrinolysis and von Willebrand factor in obese nondiabetic subjects, 1967
Weight gain
insulin resistance syndrome, risk of developing and, 1637
maternal, B85
and fetal body composition, B88–B89
and smoking cessation, and serum leptin levels in type 2 diabetes and, 516
Weight loss
caloric restriction and, in type 2 diabetes, 2
and cardiovascular risk factors, effects of monounsaturated fatty acid-enriched hypocaloric diet, 9
glycemic response to, in obesity and NIDDM, 687
monounsaturated fatty acid-enriched hypocaloric diet on cardiovascular risk factors and, in type 2 patients, 9
in type 2 diabetes, monounsaturated fatty acid-enriched hypocaloric diet and cardiovascular risk factors, 9
Well-being
and exercise in elderly type 2 diabetic patients, 2196
after nocturnal hypoglycemia, in IDDM, 341
and target levels for glycemic control in type 2 diabetes, 2085
West of Scotland Coronary Prevention Study, 165
Whitehall Study, 360
Whites. *See* Caucasians
Wisconsin Epidemiologic Study of Diabetic Retinopathy, 157, 160, 171, 236
Wolfram Syndrome, 38
Women
adverse effects of diabetes in, and risk factors for cardiovascular disease, 1258
African-American, history of gestational diabetes and metabolic alterations in nondiabetic, 1250
Caucasian, gestational diabetes testing in, 1803
gestational diabetes and, diagnostic criteria in postpartum testing of, 1579
glycemic control in, impact of pregnancy on in IDDM, 374
hormone replacement therapy and carotid wall thickness in, 1790
IDDM
glycemic control in pre-conception period and early pregnancy, effect on birth weight, 535
immunodeficiency in, 1029
older, hyperglycemia and risk of cardiovascular disease in, 1236
Pima Indian, menstrual irregularity and type 2 diabetes in, 346
postmenopausal
estrogens and risk of myocardial infarction, 1117
hormone therapy's effect on glucose and insulin concentrations in, 1589
metabolic syndrome in, 1652
NIDDM, and lower-body fat, 828
pregnant
glucose intolerance in, effects on newborn outcomes, 871
pancreatic β-cell function in, 403
with diabetes, preconception care of, S56
World Health Organization
criteria for abnormal glucose tolerance, versus American Diabetes Association, 1686
criteria for classification of gestational diabetes mellitus, B2, B6, B15–B16, B43, B138
definition of glucose intolerance, B50
global population-based estimates of diabetes prevalence, B9, B13
lack of agreement in category of impaired glucose tolerance and American Diabetes Association category of impaired fasting glucose, 1886
screening test, B15–B16
World Health Organization Study Group on Diabetes
recommendations for glucose intolerance in pregnancy, B10
Worldwide Burden of Diabetes Workshop, C1, C3, C7, C11, C15, C19, C25, C29, C30, C32, C35, C39, C44
Wound classification system, 855

Author Index

Page numbers with prefix S are found in Supplement 1 (January).
Page numbers with prefix B are found in Supplement 2 (August).
Page numbers with prefix C are found in Supplement 3 (December).

A

Aarons, J.H., 1978
Aarsen, M., 99
Abbasi, F., 1301
Abbott, C.A., 1071, 1955
Abourizk, N.N., 1364
Abraira, C., 510, 574, 669
Acampora, R., 631
Adachi, M., 2016
Adler, A.I., 563
Adler, R.A., 1596
Adler, R.G., 379
Adlerberth, A.M., 539
Agrawal, L., 510
Aguilar, C., 463
Aguilar-Salinas, C.A., 1027, 1886
Agurs-Collins, T., 876
Aharon, Y., 2194
Ahmed, A.B.E., 32, 1162, 1707
Ahmed, M.L., 831
Aiello, L.P., 143
Akaoka, I., 619
Akazawa, S., 256
Åkerblom, H.K., 1670
Albareda, M.M., 1572
Albertini, J.-P., 1008
Albisser, A.M., 591
Albus, C., 1110
Alessis, C., 2041
Alevizaki, M., 2111
Alfonsi, L., 438
Ali, S., 804
Al-Jebawi, A.F., 1364
Allannic, H., 1919
Allen, A.S., 959
Allen, H.F., 943, 2199
Aller, R., 1129
Ally, D.S., 949
Al-Mahroos, F., 936
Almirall, L., 2193
Altamirano Bustamante, N., 1372
Altman, J.-J., 196
Alvaro, M.S., 1322
Amado, J.A., 999
Ambrosch, A., 2077
Amemiya, S., 676
American Diabetes Association, 157, 179, 296, 310, 1551, 2178, 2180, S20, S23, S32, S36, S40, S45, S47, S50, S54, S56, S60, S62, S64, S66, S69, S72, S76, S77, S78, S79, S80, S82, S83, S84, S85, S86, S88, S95
Amiel, S.A., 283, 2098
Amini, S.B., 403
Amiral, J., 841
Anastasiou, E., 2111
Andersen, H., 604
Anderson, B.J., 320
Anderson, G.F., 747
Anderson, J.H. Jr., 1726
Anderson, J.W., 1596
Anderson, P.J., 379
Anderson, R.J., 1596
Anderson, R.M., 706, 1387, 1403
Andrade, R.J., 2029
André, P., 1967
Andreelli, F., 2192
Andrewes, D., 379
Anfossi, G., 121
Angius, E., 1777
Ansz, L., 216
Antoniou, A., 1004
Aoji, O., 675
Aoki, S., 1027
Aono, T., 672
Arai, K., 2135
Arakaki, R.F., 549
Arany, E., B60
Arden, N., 2069
Arfken, C.L., 792
Armstrong, D.G., 855
Arora, S., 1339
Arroyo, E., 62
Asahina, T., 1133
Ashkenazi, S., B113
The Asian Acarbose Study Group, 1058
Aso, Y., 1173
Atkinson, A.B., 677
Atsumi, Y., 116, 1133, 1373
Attali, J.-R., 1008
Attia, N., 817
Aubert, R.E., 1030, 1414, 1432
Augendre-Ferrante, B., 977
Augustin, W., 2077
Aurousseau, M.-H., 1008
Awata, T., 1569
Azouz, H., 851

B

Babaya, N., 1086
Bach, J.-F., 1371
Bajaj, M., 1330
Balançá, R., 62
Balasubramanian, S., 695
Balini, A., 1445
Balkau, B., 360
Banerji, M.A., 1377, 2129
Bangstad, H.-J., 1295, 1997
Banholzer, P., 1573
Bar, J., B113
Barbosa, K., 682
Bard, M., 2129
Bardin, C., 867
Bardini, G., 468
Barkai, L., 1019
Barnie, A., 93
Baron, A., 53
Barr, P.A., 706
Barrett, E.J., 1379
Barrett-Connor, E., 1236, 1652
Barrow, B.A., 810
Barry, D.G., 1843
Bartlay, W., 1306
Bartsocas, C.S., 462
Barzilay, J., 1659
Başçıl Tütüncü, N., 1915
Bates, M., 368
Bates, P.C., 570
Battaglia, F.C., B70
Battersby, C., 111
Baumann, C., 462
Baumgardner, G., 777
Baumgartner, R.N., 959
Bausell, B., 1282
Bax, G., 1159
Bax, J.J., 1797
Bayraktar, M., 1915
Bazzigaluppi, E., 1445
Beck, M.O., 1521
Beck-Nielsen, H., 1489
Becker, D.J., 610, 1278, 1824
Beckles, G.L.A., 1432
Beischer, W., 836
Belch, J.J.F., 1990
Belicar, P., 325, 977, 2041
Bell, D.S.H., 2028
Bell, P.M., 677
Bell, S.J., 1775
Bellio, F., 1159
Belloni, C., 1445
Bellot, V., 2029
Ben-Rafael, Z., B113
Benda, N., 271
Bennett, P.H., 127
Berg, T.J., 1295, 1997
Berger, B., 546
Berger, M., 757
Bergeret, A., 2036
Bergman, R.N., 949
Berkowitz, K., B99
Berne, C., 427
Berrazueta, J.R., 999
Bertrand, A.-M., 1146
Best, F., 1110
Best, J.D., 828
Beyer, C.S., 889
Beyer, J., 1204
Bichucher, H., 2030
Bidot, P., 2056
Bierhaus, A., 841, 1310
The BIGPRO Study Group, 1967
Binz, K., 1031
Biringer, A., B33
Birke, J.A., 23
Birkett, M.A., 570
Bittoni, M., 1240
Björk, E., 427
Blankenship, G., 143
Blaschak, J., 949
Blin, P., 977
Bloomgarden, Z.T., 183, 315, 457, 658, 860, 1024, 1198, 1356, 1560, 1764, 2023, 2185
Boehnke, M., 949
Bognetti, E., 1226
Bohannon, N.J.V., 451
Boitard, C., 191, 1371
Boivin, S., 977
Boixeda, D., 1129
Boland, E.A., 902, 909
Bonadonna, R., 221
Bonamusa, L., 2193
Bonet, R., 1517
Bonfanti, R., 1226
Bonfanti, R., 1445
Bonifacio, E., 1445
Bonnemaire, M., 196
Bonora, E., 221
Bony-Trifunovic, H., 1146
Borcea, V., 841
Borch-Johnsen, K., 877
Bortolotti, A., 1973
Bortolotti, N., 1529
Bosi, E., 1445
Boss, A.H., 1571
Bott, U., 757
Bougnères, P.-F., 1146, 2201
Boullu, S., 1575
Boulton, A.J.M., 1071, 1955
Boussairi, A., 717
Bouter, L.M., 1686, 2085
Boyle, D.I.R., 471, 738
Brambilla, G., 625
Branchi, A., 1397
Branchtein, L., 1246
Brand, J., 1044

The Brazilian Study of Gestational Diabetes (EBDG) Working Group, 1246
Bremell, T., 1217
Bretzel, R.G., 1960
Brewer, K.W., 209
Bril, V., 1749
Bringer, J., 977
Brinquin, L., 1366
Broadhurst, R.J., 637
Broch, M., 463
Brockman, D.E., 1753
Brodie, T.D., 346
Brodows, R.G., 1897
Brown, A., 2050
Brown, J.B., 1374, 1659
Brown, Z.A., 889
Bruce-Thompson, C., 711
Brun, J.-F., 2040
Brunelle, R.L., 1726
Brunner, G.A., 585
Buchanan, T.A., 949, B50, B99
Buck, C., 671
Bulpitt, C.J., 111
Burch, A., 1893
Burge, M.R., 871, 1369
Burke, J., 701
Burke, J.P., 1266
Burkert, U., 1876
Burzacca, S., 121
Buse, J.B., 1455
Bush, T.L., 1589
Butler, M., 324
Butzner, J.D., 1985
Buysschaert, M., 2200
Büyükaşik, Y., 868
Byington, R.P., 597, 2103
Byrd-Holt, D.D., 518, 1230
Byrne, J., B99

C

Caballero, A., 1517
Cabrero, D., 62
Cai, H., 1774, 2195
Cai, J., 2116
Caidahl, K., 1603
Caillat-Zucman, S., 1371
Caixàs, A., 1517
Calia, P., 625
Califf, R.M., 655
Campbell, L.V., 195, 687, 695, 2069
Campion, L., 1919
Canani, L.H., 1545
Canguçu, V., 682
Canovatchel, W., 1288
Cantero, M., 326
Cantin, B., 782
Cantón, R., 1129
Cao, H., 1203
Carantoni, M., 1301
Carel, J.-C., 1146
Carinci, F., 1439
Cario, H., 671
Caro, J.J., 1122
Carpenter, M.W., B5
Carpentier, A., 1571
Carr, S.R., B14, B123
Carrascosa, A., 1736
Carreiro Pousada, J., 682
Carrera, T., 2193
Carreras, G., 1517
Carrington, A.L., 1071, 1955
Carta, Q., 104
Carter, J.S., 770
Casamitjana-Abella, R., 62
Cascio, W.E., 2116
Castellví, A., 1517
Catalano, P.M., 403, 467, B85
Caulfield, A., 1031
Cavallerano, J.D., 143
Cavalot, F., 121
CDC Diabetes in Managed Care Work Group, 2062
Cercone, S., 1317
Ceriello, A., 327, 1529
Chacón, P., 866
Chaiken, R.L., 2129
Chan, J.C.N., 431, 1058, 1221, 2032, 2094
Chan, K.-W.A., 1058
Chang, C.-J., 1856
Chang, H.K., 549
Chang, M.-S., 1743
Chang, Y.-F., 525, 546
Chapuis, A.-S., 717
Charles, M.Al., 346, 1967
Charles, M.Ar., 2043
Chase, H.P., 209
Chast, F., 867
Chatenoud, L., 1973
Chaturvedi, N., 470
Chauffert, M., 463
Cheli, V., 1680
Chen, J.-W., 1743
Chen, Y.-D.I., 80, 1301
Cherubini, V., 2003
Chevalier, A., 717
Chevenne, D., 463
Chiano, M.N., 2069
Chiarelli, F., 2003
Chiasson, J.-L., 93, 336, 1612, 1627, 1720
The Childhood Diabetes in Finland Study Group, 1670
Chin, M.H., 1090
Chisholm, D.J., 195, 687, 695
Chiumello, G., 1226
Cho, N.H., B142
Chou, P., 1183
Chow, C.-C., 1221
Christiansen, E., 1062
Christiansen, J.S., 1062
Chrusoskie, A., 423
Chung, J., 1288
Chung, Y.E., 530
Chusney, G.D., 385
Ciampi, A., 1439
Ciuchi, E., 1680
Clapp, J.F. III, B107
Clark, C.M. Jr., 475, 883, C1, C30, C33
Clark, D.O., 195
Clarke, W., 1870
Clausen, J.T., 1997
Clelia, P., 625
Clemens, P., 836
Cockram, C.S., 431, 1221, 2032, 2094
Cohen, H.R., B33
Colagiuri, S., 1774, 2195
Colas, C., 717
Colley, D.T., 423
Colli, E., 1973
Collins, F., 949
Colly, L.P., 919
Colwell, J.A., 510, 574, 669
Comstock, J.P., 510, 574, 669, 1288
Conejo, J.R., 326
Coniff, R.F., 409, 416
Conley, M.R., 1978
Connell, F.A., 889
Connelly, P.W., 851
Connors, M.H., 831
Cook, C.B., 983, 1096
Cooper, J.W., 2197
Cooper, R.S., 1836
Cooper, T., 1240
Coppola, L., 631
Corcoran, J. Jr., 1282
Corcoy, R., 1572
Correa, A., 896
Coscelli, C., 1973
Costello, D.J., 871
Cotton, J.-B., 1146
Couch, R.M., 1691
Couillard, C., 782
Coustan, D.R., 887, B5, B161
Couvaras, O., 1146
Cowan, L.D., 1258
Cowie, C.C., 518, 1138, 1230
Cox, D.J., 1870
Craven, T.E., 2103
Crepaldi, G., 104
Crescentini, A., 1529
Critchley, J.A.J.H., 431
Crockett, S.E., 1288
Cronin, C.C., 1843
Cruickshanks, K.J., 1540
Cruz, T., 682
Cryer, P.E., 1939
Cseh, K., 1778
Csima, A., 336
Cucchiara, S., 438
Cundy, T., 1579
Curb, J.D., 549
Currie, C.J., 42
Curtillet, C., 1575
Cutler, F., 368

D

da Costa, L.A., 1521
Dacou-Voutetakis, C., 1004
Dagenais, G.R., 782
D'Agostino, R.B. Jr., 1790, 1812
Dahl, A.A., 1367
Dahl, E.M., 1367
Dahl-Jørgensen, K., 1997
Daimon, M., 1525
Dalton, D.S., 1540
Damsbo, P., 1489, 1897
Dang-Kilduff, L., B123
Danzer, G., 1876
Darmon, P., 1575, 1775
The DARTS/MEMO Collaboration, 471, 738
David, M., 506
Davidson, J.A., 409
Davidson, M., 902
Davidson, M.B., 1037, 1378, 2152
Davis, S.M., 770
Davis, T.M.E., 637
Davis, W.K., 706
Davis, W.S., 1803
de Alva, M.L., C29
de Azevedo, M.J., 1076
Debatin, K.-M., 671
Debatin, K.-M., 787
Decherney, G.S., 198
Deci, E.L., 1644
de Courten, M.P., 346
Deeb, S.S., 1194
Deepa, R., 1819
Deferrari, G., 104
de Haan, E.H.F., 1568
Dekker, J.M., 1686
de La Calle, H., 1129
de Leiva, A., 1517
Della Loggia, G., 2003

Del Ninno, M., 1317
de Lourdes Lima, M., 682
de Luis, D.A., 1129
de Neeling, J.N.D., 2085
Demacker, P.N.M., 796, 2202
Demirdjian, S., 867
The Department of Veterans Affairs Implantable Insulin Pump Study Group, 1596
Desfaits, A.-C., 487
de Sonnaville, J.J.J., 919
Després, J.-P., 782
de Veciana, M., B123
de Vegt, F., 1686
Devillé, W., 919
Dhanjil, S., 641
The Diabetes Epidemiology Research International Study Group, 1674
Diamond, J.R., 641
Dickenson, M., 291
Dierkes, J., 2077
Diez, J.J., 1029
Di Girolamo, S., 1317
Di Leo, M.A.S., 1317
Di Mauro, P., 597
Di Nardo, W., 1317
Dinneen, S.F., 972, 1408
Djilali-Saiah, I., 1371
Dobiasova, M., 139
Domínguez, C., 1736
Donaldson, C., 1370
Donker, A.J.M., 99
Donner, T.W., 1596
D'Onofrio, F., 631
Dorman, J.S., 525, 1278, 1824
Dornan, T., 930
Dornhorst, A., B43
Dost, A., 1365
Dozio, N., 1445
Dracopoulou, M., 1004
Drago, N.M., 403
Drash, A.L., 1278
Drass, J., 1282
Drayer, N.M., 831
Dubbeldam, S., 278
Dubois-Laforgue, D., 1371
Dubuisson, J.T., 1790
Ducker, L., 1579
Duckworth, W.C., 1596, 1797
Ducrocq, R., 463
Dumont, G., 265
Dunbar, V.G., 1576
Dündar, S., 868
Dunger, D.B., 831
Dunstan, F.D., 1893
Durand, G., 717
Dutour, A., 1575, 1775

E

Eastman, R.C., 331, 464, C19
Ebbesson, L., 563
Ebbesson, S.O.K., 563
Ebeling, P., 1345
Eberhardt, M.S., 518, 1578
Ebrahim, A.-R., 738
Eckert-Norton, M., 2129
Edelman, S.V., 1596
Egger, G., 221
Egusa, G., 1451
Ehnholm, C., 949
Eibl, N., 2031
Einhorn, D., 1897
Eis, A.L.W., 1753
Ekstrand, A., 1932
Elahi, D., 1326
Elbein, S.C., 1288
Elbert, K., 241
Elhadd, T.A., 1990
Elhendy, A., 1797
Elian, N., 196
Eliasson, B., 1217
Elixhauser, A., B123
El-Kebbi, I.M., 501, 1576
Elkeles, R.S., 641, 701
Elliott, J.F., 1691
Ellmerer, M., 585
Emanuele, N.V., 510, 574, 669
Embong, M., 1058
Emoto, M., 1178, 1495, 1848
Enas, E.A., 1819
Enderle, M.-D., 271
Engelgau, M.M., 1030, 1432, 2062
Equiluz-Bruck, S., 570
Erbey, J.R., 610
Ercan-Fang, N., 16, 1619
Ercan-Fang, S., 16
Erdoğan, G., 2033
Erdoğan, M.F., 2033
Eriksson, J., 949
Eriksson, J.W., 1217
Erkelens, D.W., 278
Eschwège, E., 360, 1967
Escobar-Jiménez, F., 1951
Espeland, M.A., 1589
Espina, B.M., 423
Estacio, R.O., 291
The EVADIAC Study Group, 325
Evans, G.W., 2116
Evans, J.M.M., 471
Evans, M., 2098
Evans, W.D., 1893
Everson, S.A., 1637
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 467, 469, S5

F

Facchini, F.S., 2190
Faglia, E., 625
Faja, B.W., 1455
Fajans, S.S., 466
Fajardo, M., 231
Fang, S., 1619
Farine, D., B33
Farup, C.E., 1699
Fava, D., 925
Favales, F., 625
Favre, C., 322
Fedele, D., 1159, 1973
Feher, M.D., 641
Feig, P.U., 409, 416
Feinstein, D.I., 423
Feldman, S., 196
Fernández-Castañer, M., 62
Fernández-Real, J.-M., 62
Fernlund, P., 250
Ferrara, A., 1236
Ferreira, A., 1029
Ferreira, S.R.G., 1889
Ferrière, F., 1008
Ferris F.L. III, 143
Ferriss, J.B., 1843
Fiehn, W., 841, 994
Fineberg, S.E., 1589
Fineman, M.S., 668
Fink, L.M., 1028
The FINMONICA Myocardial Infarction Register Study Group, 69
Fischer, J., 2050
Fitzgerald, J.F., 1380
Fitzgerald, J.T., 706, 1403
Flaherty, B.P., 915
Flegal, K.M., 518, 1578
Fleming, B., 1282
Fletcher, A.E., 111
Fleury, A.C., 695
Foerster, H., 1110
Folsom, A.R., 324, 2116
Fonfrède, M., 463
Fonseca, V.A., 1028
Forhan, A., 360
Forrester, T., 1836
Forsbach, G., 873
Forsblom, C.M., 1932
Forse, R.A., 1775
Fowelin, J., 1217
Franco, L.J., 1246, 1889
Franzese, A., 38, 438
Fraser-Reynolds, K.A., 1985
Frazer de Llado, T.E., 744
Fredriksson, L., 1217
Freedman, Z.R., 1644, 2056
Freeman, R., 1339
The French Pediatric Diabetes Group, 1146
Fried, S., B113
Friedberg, C.E., 494
Friedman, M., 1240
Friedman, N.M., 871, 2062
Friedmann, R., 2030
Frier, B.M., 26, 199, 470
Fritsche, A., 1505
Frohlich, J.J., 139
Frost, D., 836
Fruehwald-Schultes, B., 1204
Fryback, D.G., 725
Frykberg, R.G., 1339, 1714
Fuh, M.M.C., 1058
Fujii, S., 482, 1353
Fujisawa, T., 1086
Fujishima, M., 516
Fujita, T., 672
Fujita, Y., 2140
Fujiwara, Y., 1173
Fukuda, K., 1632
Fukui, M., 675
Fukushima, N., 1632
Fuller, J.H., 470
Funakoshi, S., 2037
Funato, H., 619
Fung, C.M., B85
Funnell, M.M., 706, 1403
Furberg, C.D., 2103
Furler, S.M., 687
Furth, E.D., 555

G

Gabbe, S.G., 467, B1
Gaillard, T.R., 1250
Gale, E.A.M., 1726
Gallenga, P.E., 2003
Gallina, D.L., 501, 1576
Galun, R., 2030
Ganapathi Sastry, N., 1819
Gandara, S., 423
Gannon, M.C., 16, 1619
Garandeau, P., 1146
García-Escaño, M.D., 2029
García-García, E., 1027
García-Unzueta, M.T., 999
Gardner, S., 925
Gardner, T.W., 143
Gare, D.J., B33

Garg, S.K., 209
Garry, P.J., 959
Gaskill, S.P., 1167, 1266
Gattegno, L., 1008
Gavin, J.R. III, 467, 468, 469
Gay, E.C., 943
Geiss, L.S., 2062
Geleijnse, M.L., 1797
Gendrault, B., 1146
Gerchman, F., 1545
Gerdes, L.U., 1062
Gerich, J.E., 1505, 1939, 1960
Ghazzi, M.N., 1462
Ghirlanda, G., 1317
Ghosh, S., 949
Giani, G., 389
Giannaki, M., 1004
Gibson, J.L., 1753
Gilead, L., 2030
Giles, G.G., 828
Gillery, P., 265
Gillet, P., 1146
Gilliland, S.S., 770
Gilmore, S., 231
Gimeno, S.G.A., 1889
Giobbie-Hurder, A., 1596, 1797
Gipson, M.T., 1046
Giugliano, D. 327, 631
Giunta, R., 631
Giusti, R., 1680
Glauber, H., 1374
The Glimepiride Combination Group, 1052
Go, O.T., 563, 1258
Goberna, R., 1951
Godaert, G.L.R., 2196
Goh, K.L., 2047
Gold, A.E., 199, 374, 535
Goldberg, D.E., 1637
Goldberg, R.B., 591, 1897
Golden, M.P., 885
Goldstein, D.E., 518, 1215
Gómez Pérez, F.J., 1027, 1886
Gomis, R., 1720
Gonder-Frederick, L.A., 1870
Gonzalez de Pijem, L., 744
González Sanguineti, A., 1577
González, A., 1951
Gorman, C.A., 972
Gorson, D.M., 2190
Gottsater, A., 250
Grabert, M., 787
Grandinetti, A., 549
Granger, C.B., 655
Grant, C.T., 16
Grant, W., 241
Gravholt, C.H., 1062
Greene, S.A., 1990
Greer, I.A., 1753
Gregg, E.W., 875
Grey, M., 902, 909
Gries, F.A., 389
Grobbee, D.E., 494
Groenewoud, H.M.M., 190
Groop, L., 1932
Groop, P.-H., 1932
Grootenhuis, P.A., 2085
Gross, J.L., 1076, 1521, 1545
Großmann, R., 1960
Grüb, M., 1505
Gruppen, L.D., 1403
Gruppo Italiano Studio Deficit Erettile nei Diabetici, 1973
Gu, K., 1138
Guarisco, R., 597
Gudat, U., 800
Guerci, B., 977
Guerre-Millo, M., 717
Guilhem, I., 1919
Guillaume, V., 1775
Guillen-Pineda, L.E., 1886
Gumbiner, B., 9, 1455
Guralnik, J.M., 193
Gussinye, M., 1736
Gutierrez,C., 463
Guttmann-Bauman, I., 915

H

Haag, B., 2056
Haastert, B., 389
Hadden, D.R., 677, B3
Haering, H.U., 271
Haffner, S.M., 69, 160, 409, 1167, 1266, 1790, 1812, C3
Haglid, M., 1603
Hagopian, W.A., 949
Halter, J.B., 1828
Hama, K., 1525
Hamada, M., 672
Hamada, Y., 1014, 1086
Hamilton, B.P., 1596
Hamman, R.F., 53, 943, 1035
Hanaire-Broutin, H., 977
Hanefeld, M., 1720
Hanley, A.J.G., 322, 851, 870, 1203
Hänninen, T., 398
Hanson, R.L., 346
Hanson, U., B79
Hanssen, K.F., 1295, 1997
Harada, S., 1632
Häring, H.-U., 836, 1505
Harkless, L.B., 855, 1714
Harper, R., 677
Harris, M.I., 331, 518, 1138, 1230, C11
Harris, S.B., 322, 851, 870, 1203
Hartford, M., 1603
Harvey, C., 1714
Hasslacher, C., 994
Hauptman, J., 1288
Hauser, E.R., 949
Havelec, L., 580
Hawk, B., 744
Hawley, G., 368
Hayashi, R., 672
Hayashi, T., 1774
Hays, L.M., 195
Haznedaroğlu, İ.C., 868
Heckbert, S.R., 1117
Hegele, R.A., 322, 851, 1203
Heikkinen, S., 849, 1194
Heine, R.J., 494, 919, 1568, 1686, 2039, 2085
Heinemann, L., 461, 800, 1910
Heinrichs, S., 800, 1910
Heinze, E., 787
Heise, T., 800, 1910
Helbers, L., 1699
Helkala, E.-L., 398
Helmrich, S.P., 1637
Helve, E., 477
Henderson, W.G., 510, 574, 1596, 1797
Henkels, M., 841
Henning, A., 1110
Henry, R.R., 1596
Herbreteau, C., 1502
Herlitz, J., 1603
Herman, W.H., 1030, 1414, 1432, C19
Hermann, L.S., 1489
Hermans, M.P., 2200, 2191
Hermos, R.J., 197
Hernández, C., 866
Herpertz, S., 1110
Herrington, D.M., 1790
Herson, M.K., 1659
Hess, G.E., 706
Hickey, M.E., 770
Higashi, S., 1774
Hill, D.J., B60
Hillenaar, E.F., 2196
Hirano, T., 2016
Hirasing, R.A., 190
Hirsch, I.B., 1288
Hiss, R.G., 706
Hitchcock Noël, P., 896
Hitchman, R., 674
Hiura, Y., 1178
Ho, L.L.T., 1058
Hobbs, M.S.T., 637
Hod, M., B113
Hodak, E., 506
Hoekstra, J.B.L., 2196
Hofmann, M.A., 841, 1310
Hogan, P.E., 1589
Holcombe, J., 817
Holing, E.V., 889
Holl, R.W., 671, 787
Hollander, P.A., 1288
Hollis, S., 930
Holman, R.R., 810
Holmes, L., 1978
Holst, J.J., 1925
Holzapfel, S., B33
Home, P.D., 32, 1162, 1707, 1904
Homko, C.J., B118
Hong, S.-K., 134, 530, 2149
Hopkins, D., 283, 2098
Hori, M., 2123, 2135
Horn, L.C., 1058
Horton, E.S., 1462
Hosokawa, K., 1133
Hother-Nielsen, O., 1489
Hotsubo, T., 1632
Hotta, N., 1014
Howard, B.V., 1258, 2201
Howard, G., 1589
Howard, W.J., 2201
Hsu, N.-W., 1743
Huang, W.-C., 1897
Hummel, M., 1573
Hundley, R., 959
Hunt, J.A., 336, 1612
Hurley, J.S., 2062
Huschka, T.R., 972
Huston, L.P., B85
Hylleberg, B., 1904

I

Iafusco, D., 1379, 1777
Iglesias, P., 1029
Ikegami, H., 1086
İleri, N.Ş., 868
Ilmonen, M., 477
Imanishi, M., 482
Imano, E., 2135
Imperatore, G., 649., 2041
Inaba, M., 1178, 1495
Ingber, A., 2030
Inoue, I., 1569
Inoue, K., 1569
Inoue, T., 619
Inukai, T., 1173
The Investigators of the TRANSFERT Study, 196
Ioffe-Uspensky, I., 2030
Iovine, C., 649

Ip, T.P., 1154
Ireland, P.D., 828
Ishibashi, S., 192
Ishii, C., 1569
Ishii, T., 1353
Ishikawa, S., 1376
Ishimura, E., 1178, 1495, 1848
Ishiyama, S., 753
Islam, H.N., 385
Isotani, H., 2034
Itabashi, N., 1376
The Italian Microalbuminuria Study Group in IDDM, 104
Ito, M., 49
Ito, Y., 1632
Itoh, M., 672
Itzhak, M., B113
Iula, V.D., 438
Iunes, M., 1889
Iwamoto, K., 615
Iwamoto, Y., 1080, 2144
Iwasaki, N., 2144
Iwasaki, R., 2037
Izumotani, K., 1178

J

Jablonski, K., 246
Jacobsen, P., 2007
Jain, A., 2050
Jain, S.K., 1375, 1511
Jakicic, J.M., 350
James, S.A., 555
Jamjoum, L., 555
Jamrozik, K., 637
Janes, J.M., 2098
Janisse, D., 2161
Janssen, M.J.F.M., 494
Jäntti, V., 1101
The Japanese-Brazilian Diabetes Study Group, 1889
Jaramillo, J.J., 1511
Jaremko, J., 444
Jarrett, R.J., 360
Jeandidier, N., 977
Jeffers, B., 291
Jen, S.-L., 1743
Jenkins, A.B., 687, 695
Jiao, Y., 1732
Johnson, D.W., 53
Johnson, S.B., 213
Johnston, D.G., 701
Johnston, P.S., 409, 416
Jones, J.S., 831
Jones, T.W., 817
Jongbloet, P.H., 190
Jönsson, B., C7
Jos, J., 1146
Joseph, S.E., 2098
Josse, R.G., 1612, 1720
Joswig, M., 1310
Jovanovic, L., 1978, B131
Juhan-Vague, I., 1967
Julka, I.S., 1322
Jung, R.T., 471, 738

K

Kaarsalo, E., 477
Kado, S., 1759
Kajimoto, Y., 2135
Kajiyama, S., 615
Kakizawa, H., 672
Kalhan, S.C., B75
Kamado, K., 2123
Kamel, N., 2033
Kameoka, K., 2034
Kanazawa, Y., 1569
Kanda, H., 1178
Kanda, T., 2135
Kanitz, M., 1310
Kapellen, T.M., 1365
Kaplan, G.A., 1637
Kaplan, R.A., 1288
Kaplan, R.C., 1117
Karaahmetoğlu, S., 868
Karasik, A., 1720
Kareinen, A., 849
Karjalainen, J., 1670
Karlson, B.W., 1603
Karlsson, F.A., 427
Karlsson, T., 1603
Karp, M., 506
Kartnig, I., 462
Karvonen, M., 1101
Kasahara, T., 2144
Kashiwazaki, K., 2016
Kass, M., 246
Kastrup, J., 804
Kasuga, A., 2037
Katamura, M., 320
Katayama, S., 1569
Kato, T., 1525
Katsura, Y., 1759
Katz, I., B113
Kauma, H., 1188
Kavanagh, P.L., 1122
Kawabata, Y., 1086
Kawagishi, T., 1178, 1495, 1848
Kawaguchi, Y., 1086
Kawamori, R., 116, 1133
Kawano, K., 1027
Kawasaki, T., 619
Kazmi, F., 385
Keeffe, J.E., 324
Keevil, B.G., 261, 1578
Keinänen-Kiukaanniemi, S., 1664
Kekäläinen, P., 1194
Kell, S., 1282
Kelley, D.E., 2, 416, 1288, 1596, 2056
Kelly, P.E., 1367
Kelly, P.J., 2069
Kelnar, C.J.H., 1567
Kemperman, F.A.W., 216
Kenshole, A.B., B33
Kern, W., 1204
Kesäniemi, Y.A., 1188
Khan, F., 1990
Khazanie, P.G., 555
Kiechl, S., 221
Kiess, W., 1365
Kilkki, E., 477
Kilpatrick, E.S., 261, 1578
Kim, C.-H., 134, 2149
Kim, D.-K., 1058
Kim, H.-K., 134, 530
Kim, S.-W., 134, 530
Kimura, G., 482
Kimura, M., 1525
King, G.L., 143
King, H., 1414, B9
King, P., 341
Kinney, E.K., 549
Kinoshita, J., 1133
Kinsley, B.T., 1330
Kirk, G., 1990
Kirkman, M.S., 1596
Kirkpatrick, K.A., 213
Kistler, J., 1775
Kitagawa, Y., 615
Kitaoka, H., 2034
Kitzmiller, J.L., B123
Kırazlı, Ş, 868
Kjos, S.L., B50, B99
Klapp, B.F., 1876
Klee, G.G., 1408
Klein, B.E.K., 236, 725, 1375, 1540, C39
Klein, R., 143, 236, 725, 792, 1230, 1375, 1540, C39
Klevesath, M.S., 1310
Klingensmith, G.J., 943
Knip, M., 1670
Knobler, R., 580
Knopp, R.H., 1978
Knowler, W.C., 127, 346, B138
Knudson, P.E., 1029
Ko, G.T.C., 1221, 2032, 2094
Kobayashi, A., 2037
Kobayashi, I., 1470
Kocnar, M., 1110
Koda, J.E., 668
Koehler, K.M., 959
Kogure, A., 465
Koh, N., 1014
Kohl, B., 841
Köhle, K., 1110
Kohne, E., 671
Kohno, S., 753
Kohtamäki, K., 949
Koike, A., 1632
Koivisto, K., 398
Koivisto, V.A., 1345, 1726
Kolterman, O.G., 987
Kondo, M., 465, 615, 675
Kong, M.-F., 341
König, W., 2077
Konishi, Y., 482
Kopf, D., 2077
Korytkowski, M.T., 1939
Korzon-Burakowska, A., 283, 2098
Kosano, H., 1759
Koshibu, E., 619
Koshiyama, H., 323
Kossen, N.W., 1481
Kostense, P.J., 2085
Kotsanos, J.G., 1240
Kovács, M., 1778
Kovatchev, B.P., 1870
Koyama, K., 753
Koyama, W., 753
Koyanagi, A., 753
Kraegen, E.W., 687
Krediet, R.T., 216
Krejs, G.J., 585
Kritchevsky, S.B., 193
Kritz-Silverstein, D., 1652
Krol, A., 409, 416, 2050, 2056
Krop, J.S., 747
Krueger, K.S., 1511
Kühl, C., B19
Kuller, L.H., 610, 1278
Kumanyika, S.K., 876
Kumar, D., 1322
Kurihara, S., 1569
Kuroda, Y., 49
Kurokawa, M., 2016
Kuroki, H., 2144
Kusuoka, H., 2123
Kuusisto, J., 398, 1194
Kuwao, S., 2140
Kuzuya, T., 1569

L

Laakso, Mar., 398, 477, 849, 1194, 1720

Laakso, Mau., 1664
Lacroix, C., 2036
Lafuma, A., 1146
Lahera, M., 1129
Lakatos, P., 1778
Lakhdar, A., 461
Lakka, T.A., 1637
Lalau, J.D., 1366, 2036
Lalitha, S., 1205
Lam, K.S.L., 1154
Lamarche, B., 782
Lambert, J., 99
Lamonica, M., 1159
Landon, C., 80
Landoni, M., 1973
Lang, W., 350
Lange, F., 1502
Langefeld, C.D., 949
Langer, O., B91
LaPorte, R.E., 525, 1278, 1372, 1674, 1824
Larger, E., 1371
Larme, A.C., 896, 1391
Lassman, M.N., 1364
Lassmann-Vague, V., 325, 977, 2041
Latare, P., 1659
Latha, E., 76, 666, 967
Laugier, A., 1575
Launay, B., 1627
Lauritzen, E., 2007
Lavery, L.A., 855, 1714
Lawday, K., 1571
Laws, A., 1790
Lebovitz, H.E., 1377, 2129
Lee, E.T., 1258
Lee, H.-L., 1856
Lee, K.-U., 134, 530, 2149
Lee, P., 930
Lee, V., 1310
Lee, W.-L., 1743
Lee, Y.J., 1978
Leese, G.P., 738
Le Floch, J.-P., 1502
Lehnert, H., 2077
Lehotay, D.C., 1306
Lehto, S., 69, 849
Leibson, C.L., 1408
Leidy, N.K., 1699
Lejeune, P.-J., 2041
Lekakis, J.P., 2111
Leludas, C., 1365
Le luyer, B., 1146
Lemole, G.M., 198
Lenhard, M.J., 198
Le Prieur, N., 1919
Lerman-Garber, I., 1027
Leslie, R.D.G., 925
Leturcq, F., 1146
Levetan, C.S., 246
Levin, M.E., 1, 681
Levin, S.R., 510, 574, 669
Levy, C.J., 1330
Levy, J.C., 810, 2191
Lewis, G.F., 1571
Li, C.-L., 1183
Li, H., 1408
Li, J.K.Y., 1221
Li, T., 525
Li, Y., 525
Liang, H.C., 959
Liao, D., 2116
Libman, I.M., 1278, 1372, 1824
Liese, A.D., 2116
Ligtenberg, P.C., 2196
Lilja, M., 1188
Lin, S.-J., 1743
Lin, X., 1828
Lindelöw, B., 1603
Lindeman, R.D., 959
Lindgarde, F., 250
Lindholm, A., 1904
Little, J., 535
Little, J.A., 874
Little, R.R., 518
Littlejohn, T., 2050
Livingston, P.M., 324
Lizzio, S., 1529
Llewelyn, J., 1726
Lobefalo, L., 2003
Lobón, J.A., 1951
Lodewick, P.A., 1288
Loebstein, R., 1306
LoGerfo, F.W., 1339
Loh, K.-C., 139
Lomas, J., 283
López-Alvarenga, J.C., 1886
Lorenz, R., 2021
Lormeau, B., 1008
Lougheed, W.D., 874
Low, C.C., 9
Lowery, J., 777
Lu, F.-H., 1856
Lucas, C.P., 1288., 1897
Lucena, M., 2029
Lukács, K., 1019
Luley, C., 2077
Lund-Andersen, H., 2007
Luo, J., 717
Luo, X., 1306
Lupien, P.-J., 782
Luzio, S.D., 1893
Lyall, F., 1753
Lynch, J.W., 1637

M

MacDonald, T.M., 471, 738
Macdonald, I., 283, 341
Maekawa, K., 1178
Magnani, P., 1317
Magner, J., 2050, 2056
Magnuson, V., 949
Mahler, R., 1960
Mahmood, S., 641
Mähönen, M., 69
Major, C.A., B123
Makino, M., 615, 672
Maldonado, D. III, 1408
Mallias, J., 1162
Manaka, H., 1525
Mangili, R., 104
Mann, K., 1110
Manninen, D.L., 2062
Mannucci, E., 468
Marfella, R., 631
Marin, N., 1159
Markovic, T.P., 687, 695
Marlin, K.L., 1691
Marsh, G., 896
Marshall, H.J., 1322
Martí, R., 866
Maruyama, T., 2037
Maser, R.E., 198
Masse, J., 878
Massucco, P., 121
Mastropasqua, L., 2003
Mather, H., 641
Mathias, N.P., 1455
Mathur, G., 674
Matsuda, J., 49
Matsumoto, K., 256, 673, 1206
Matsumoto, N., 1495
Matsuoka, K., 116, 1133, 1373
Matsuoka, T., 1759
Matsushima, M., 1674
Matsuura, N., 1632
Matthews, D.R., 2191
Mattiello, L., 121
Mattock, M.B., 385
Matyka, K., 283
Mau, M.K., 549
Maugendre, D., 1919
Mauriège, P., 782
Mayer, A.M., 563
Mayfield, J.A., 2161
Maylor, P.W., 261, 1578
McAlpine, R., 738
McArthur, K., B33
McCalman, R., 770
McCraw, M., 983
McDonald, R.C., C25
McElduff, A., 674
McEvoy, R.C., 915
McFarlane, S., 1377
McGill, J., 1288
McGwin, G. Jr., 877
McKeigue, P.M., 936
McLaren, M., 1990
Mcleod, J., 1369
McMahon, A.D., 471
McNicholas, K.W., 198
McPartlin, J.M., 1843
McVie, R., 1511
Megas, J., 2111
Meier, M., 1044
Melga, P., 1680
Melki, V., 977
Melton, L.J. III, 1408
Mendelson, R.A., 711
Meneghini, L.F., 591
Meneilly, G.S., 1326
Mercadier, A., 1371
Mercier, J., 2040
Meredith, V., 1096
Merrell, K., 1090
Mesa, J., 866
Meschi, F., 1226, 1445
Metzger, B.E., 1978, B142, B161
Mevorach, M., 2194
Meyer, C., 1960
Meyer, J., 896
Meyer, L., 977
Miele, M.E., 198
Miettinen, H., 69
Millan, M., 1203
Miller, J., 2030
Mills, J.L., 1978
Minamikawa, J.,323
Mintz, D.H., 591
Mitchell, M.L., 197
Mitrakou, A., 1939, 1960
Miuira, J., 1080
Miyake, S., 256, 673, 1206
Miyamori, I., 1774
Miyashita, H., 619
Mogensen, C.E., 97, 878
Mohamed-Ali, V., 127
Mohan, R., 2198
Mohan, V., 1819, 2198
Mokan, M., 1939
Montalbán, C., 999
Montisci, A., 438
Montoro, M., B99
Mooradian, A.D., 416

Moorjani, S., 782
Morabito, A., 625
Morange, P., 1967
Morcos, M., 1310
Moreira, F.L., 438
Moreno, P., 2029
Morgan, C.Ll., 42
Morgan, N.A., 1596
Morgese, G., 2003
Mori, M., 1470
Morii, H., 1178, 1495, 1848
Morimoto, J., 2037
Morley, J.E., 231
Morozumi, T., 2123
Morris, A.D., 471, 738
Morrison, E., 191
Morrison, J., 1579
Morrison, S.F., B156
Moses, J., 1803
Moses, M., 1807
Moses, R.G., 674, 1803, 1807
Moskowitz, A., 1282
Moss, S.E., 236
Motomura, M., 2135
Motz, E., 1529
Mourlhon, C., 2036
Müftüoglu, O., 868
Muggeo, M., 221
Mühlen, I., 2077
Mühlhauser, I., 461, 757
Mularoni, E.M., 121
Mullen, M.L., 2
Mullooly, C.A., 1775
Mumcuoglu, K.Y., 2030
Muntoni, Sa., 1101
Muntoni, Se., 1101
Murphy, M.E., 972
Murray, M., 1699
Mutou, K., 1080
Myatt, L., 1753
Mykkänen, L., 398, 1194

N

Nadeau, D., 2050
Naeraa, R.W., 1062
Naessens, J.M., 972
Nagasaka, A., 672
Nagasaka, S., 1376
Nagata, M., 672
Nagata, S., 2123
Nagi, D.K., 127
Nagy, Z., 1778
Naito, E., 49
Nakamura, J., 1014
Nakamura, N., 615, 675
Nakano, K., 615, 675
Nakatani, Y., 2135
Nakayama, H., 2123
Naliboff, B.D., 231
Namai, K., 1569
Nanto, S., 2123
Narayan, K.M.V., 875
Nassif, X., 191
The Native Hawaiian Health Research (NHHR) Project, 549
Nauck, M.A., 1925
Navalesi, R., 104
Navarro, J.M., 2193
Nawroth, P.P., 841, 1310
Naylor, C.D., B33
Negishi, K., 1569
Nelson, D.M., 1455
Neufeld, N.D., 80
Newton, K.M., 1117
Newton, P., 930
Newton, R.W., 471, 738, 1990
The NICHD-Diabetes in Early Pregnancy Study Group (DIEP), 1978
Nicholls, G., 431
Nichols, G., 1374
Nicolaides, A.N., 641
Nicolucci, A., 1439
Nielsen, F.S., 804
Niemelä, M., 69
Nierop, P.R., 1797
Nijpels, G., 1686
Nishida, T., 2135
Nishigori, H., 1759
Nishimura, C., 1014
Nishimura, R., 1674
Nishimura, T., 2123
Nishizawa, Y., 1178, 1495, 1848
Niskanen, L., 1861
Nissinen, A., 1349
Nojima, K., 1086
Nonaka, K., 753
Noritake, M., 1759
Northam, E.A., 379
Nosadini, R., 104
Noth, R., 677
Nourooz-Zadeh, J., 1295
Nucci, L.B., 1246
Nuttall, F.Q., 16, 510, 574, 669, 1475, 1619
Nyholm, B., 1062
Nylund, S.J., 949

O

Oats, J.J.N., B58
Obayashi, H., 675
Oberhollenzer, F., 221
O'Brien, J.A., 1122
Odawara, M., 199
O'Dea, K., 828
Odetti, P., 1680
Ogata, M., 2144
Ogata, N., 619
Ogihara, T., 1086
Ognibene, A., 468
Oh, J., 324
Ohara, T., 2123
Ohashi, K., 192
Ohgaki, K., 615
Ohnishi, K., 1027
Ohnuma, H., 1525
Ohsawa, N., 2034
Oida, K., 1774
Okamura, T., 1848
O'Kane, M.J., 677
Okano, T., 1759
Okosun, I.S., 1836
Okubo, M., 1451
Okudaira, M., 1080
Okumiya, T., 1732
Okuno, A., 1632
Okuno, Y., 1178, 1495, 1848
Oliveira, J., 1076
Oliver, C., 1575, 1775
Ollendorf, D.A., 1240
Ollerton, R.L., 1893
Onishi, N., 320
Ono, Y., 1027
Onuma, T., 116, 1133
Oppert, J.-M., 717
O'Rahilly, S., 668
Orban, T., 197
Orchard, T.J., 321, 610
Ordóñez-Llanos, J., 1517
O'Regan, M., 1567
The Organizing Committee, B161
Orians, C.E., 2062
Osborn, M., 1282
Osei, K., 1250
Osinga, J., 800
Osotimehin, B., 1836
Oster, G., 1240
Otani, T., 1080
Ovalle, F., 2028
Ovalle, K.B., 1775
Overmann, H., 461, 757
Owen, C.L., 770
Owen, S., 209
Owens, D.R., 1893
Ozawa, Y., 2037

P

Pagnoux, C., 191
Pahor, M., 193, 597, 2103
Päivänsalo, M., 1188
Palmason, C., 336, 1612
Palmer, A.J., 111
Palmer, M., 1511
Palmisano, J., 2129
Paludetti, G., 1317
Panelo, A.A., 1058
Papamichael, C.M., 2111
Parazzini, F., 1973
Paris, I., 2200
Park, E., 1978
Park, H.-J., 2149
Park, J.-Y., 134, 530, 2149
Park, K., 1732
Parkin, H., 341
Parra, T., 326
Parsons, R.W., 637
Parving, H.-H., 804, 1534, 1779, 2007
Passaro, M., 246
Pastore, M.R., 1445
Payne, M.J., 810
Peacock, S.J., 871
Pearson, L., 987
Pedula, K., 1659
Peled, Y., B113
Penman, A., 1096
Penttilä, I., 1861
The PEPI Investigators, 1589
Peppa-Patrikiou, M., 1004
Perez, G.E., 770
Pérez, A., 1517
Perez-Jauregui, J., 1886
Perez-Martin, A., 2040
Perlemuter, L., 1502
Pernet, A., 283
Perry, I.J., 732
Persson, B., B79
Pesquera, C., 999
Peters, A., 1204
Peters, A.L., 1037
Peters, J.R., 42
Peters, R.K., B50, B99
Petrik, J., B60
Petterson, T., 930
Pettitt, D.J., 346, 1789, B138
Pfohl, M., 271, 836
Pfützner, A., 1204
Pham, H., 1714
Philippe, J., 1031
Phillips, D.I.W., B150
Phillips, L.S., 501, 1576
Piarulli, F., 1159
Piccolo, I., 1777
Pickstock, P.G., 1567
Pickup, J.C., 385

Pieber, T.R., 585
Pietropaolo, M., 1824
Pitteloud, N., 1031
Playle, R., 1893
Plotton, I., 2192
Podlecki, D., 2056
Pogach, L.M., 368, 2161
Poggi, V., 38
Poirier, J.-Y., 1919
Poldermans, D., 1797
Polley, B.A., 350
Ponziani, M.C., 121
Poon, E., 431
Poulsen, P.L., 97
Poulter, C., 641
Pouwer, F., 2039
Powe, N.R., 747
The Pramlintide in Type 2 Diabetes Group, 987
Prando, R., 1680
Prashanth Haranath, S., 1819
Prela, C.M., 777
Premalatha, G., 1819
Prins, A.M., 216
Prisco, F., 1379, 1777
Psaty, B.M., 1117
The Puerto Rican IDDM Coalition, 744
Pugh, J.A., 896, 1391
Puig, M., 1572
Pulkkinen, A., 849
Pyke, D., 925
Pyörälä, K., 69, 360
Pyörälä, M., 360

Q

Qiao, Q., 1349, 1664
Quarantiello, A., 625
Quehenberger, F., 585
Quigley, E.M.M., 1699
Quinn, M., 197

R

Rabl, W., 1573
Race, J.-M., 1366
Rachman, J., 810
Raffel, L.J., 80
Raggio, G., 1122
Raghunathan, T.E., 555
Raj, D., 2198
Rajala, U., 1664
Ramachandran, A., 76, 666, 967, 1205
Rampoldi, A., 625
Rantala, A.O., 1188
Rarick, M.U., 423
Raskin, P., 1694
Rassam, A.G., 1369
Rathmann, W., 389
Ratner, R.E., 246
Rauhaus, M., 1910
Raynaud, E., 2040
Raz, I., 2030
Rea, F., 1379
Reaven, G.M., 1301
Reaven, P.D., 9
Redmon, J.B., 1944
Reece, E.A., B118
Regensteiner, J.G., 291
Reiber, G.E., 777, 2161
Reichelt, A.J., 1246
Reilly, C., 374
Reilly, R., 535
Rema, M., 1819
Renard, E., 977
Rendell, M.S., 1897, 2056
Renier, G., 487
Renn, W., 1505
Reno, P.L., 792
Repke, D., 368
Resnick, H.E., 1828
Reunanen, A., 1188
Reviriego, J., 1203
Rewers, M., 1790, 1812
Reynolds, T., 1028
Ricart-Engel, W., 62
Riccardi, G., 649, 2041
Richart, C., 463
Richmond, W., 641
Riddle, M.C., 1052, 1389
Riekkinen, P. Sr., 398
Riou, J.P., 2192
Risica, P.M., 563
Rissanen, J., 1194
Ritchie, J.W.K., B33
Ritzel, R., 1925
Riva, M.C., 1226
Rivellese, A.A., 649
Rizkalla, S.W., 717
Rizza, R.A., 972, 1408
Rizzo, T.A., B142
Roach, P., 800
Robbins, D.C., 563, 1258
Roberts, R., B27
Roberts, W.L., 983
Robertson, R.P., 1944
Robins, L.S., 1387
Robinson, A.C., 701
Robinson, S., 701
Robles Valdes, C., 1372
Rode, S., 322
Rodger, N.W., 1612
Rodrigues, L.E., 682
Roelandt, J.R.T.C., 1797
Rokkaku, K., 1376
Rolfsen, R.J., 23
Romero, L.J., 959
Rorstad, O., 444
Rose, M., 1876
Roseman, J.M., 389, 877
Rosengren, A., 539
Rosenn, B., 200
Rosenstock, J., 2050
Rosenthal, M.J., 231
Rosilio, M., 1146
Ross, E., 949
Ross, L., 1567
Ross, S.A., 336, 1612
Rossi, M., B43
Rossing, K., 2007
Rossing, P., 1779, 2007
Rotella, C.M., 468
Roth, J., 1781
Rotimi, C.N., 1836
Roubicek, M., 1577
Roumain, J., 346
Round, P., 1904
Rovellini, A., 1397
Rowland, M., 1230
Rueda, O.A., 1372
Ruiz, E., 1736
Rull, J.A., 1027, 1886
Russell, K.G., 1807
Russo, A., 1529
Ryan, E.A., 336, 1612

S

Saad, M.F., 1790
Saarinen, L., 849, 1194
Sachimechi, I., 2129
Sagum, R., 549
Saibara, T., 1732
Saigenji, K., 2140
Sainfort, F., 725
Saito, T., 1376
Sakakibara, F., 1014
Sakamoto, K., 2123
Sakane, N., 320, 465
Salamon, F., 1778
Salmerón, F.J., 2029
Salomaa, V., 69
Salonen, J.T., 1349, 1637
Salonen, R., 1349
Saloranta, C., 1932
Saltevo, J., 477
Salvia, L., 438
Samaras, K., 195, 2069
San Román, A.L., 1129
Sánchez-Margalet, V., 1951
Sanders, L.J., 2161
Sandholzer, K., 570
Sane, T., 1932
Sanmarco, M., 2041
Santeusanio, F., 104, 1973
Santiago, J.V., 792
Saponara, C., 1317
Saruta, T., 2037
Sasaki, M., 1732
Sato, A., 804, 1534
Sato, H., 320
Sato, N., 1470
Sato, T., 482, 1353
Satou, A., 1080
Satyavani, K., 76, 967
Saudek, C.D., 747, 1596, 1797
Sauerwald, A., 1925
Savage, P.J., 1812
Savin, S., 867
Savolainen, M.J., 1188
Sawada, M., 675
Sawin, C.T., 368, 510, 574, 669
Schade, D.S., 959, 1369
Schaefer, U., B50, B99
Schaupp, L., 585
Schernthaner, G., 570, 1778, 2031
Schiebe, H., 368
Schiekofer, S., 1310
Schier, G.M., 1807
Schimel, D., 2056
Schindel, B., B113
Schindl, A., 580
Schindl, L., 580
Schindl, M., 580
Schirop, T., 1876
Schlundt, D., 1870
Schmidt, A.M., 841
Schmidt, M.I., 1246
Schmiegel, W., 1925
Schmitz, O., 1062
Schmuelling, R.-M., 271, 1505
Schnack, C., 2031
Schneider, J., 1052
Schnell, O., 1044
Schnoll, R.A., 1046
Schoenfeld, S.L., 987
Scholler, G., 1876
Schön, H., 580
Schoonen, A.J.M., 1481
Schraer, C.D., 563
Schranz, A.G., 194
Schrier, R.W., 291
Schrott, H., 1589
Schulman, H., 2030
Schulze Schleppinghoff, B., 1110
Schuster, D.P., 1250

Scordili, M., 1004
Scott, J.M., 1843
Scott, R.B., 1985
Sedore, A., 1029
Seena, R., 1205
Sélam, J.-L., 867
The SENDCAP Study Group, 641
Sendlhofer, G., 585
Senf, W., 1110
Ser, N., 1146
Sergi, A., 1445
Sermer, M., B33
Serra, A.J., 198
Serri, O., 487
Service, F.J., 469
Serwas, A., 800
Shaffer, T.J., 747
Shahar, E.,324
Shamoon, H., 2194
Shaper, A.G., 732
Sharp, P., 641
Sharrett, A.R., 2116
Shatin, D., 2062
Shaw, J.E., 1955
Sheaves, R., 1058
Shen, G.-Q., 1086
Sher, G.D., 1306
Shetterly, S.M., 53
Sheu, W.H.-H., 1575
Shibuya, A., 2140
Shigeta, H., 615, 675
Shima, K., 49
Shimada, A., 2037
Shimada, H., 1495
Shimizu, H., 1470
Shimomura, Y., 1470
Shimonagata, T., 2123
Shinohara, R., 672
Shintani, M., 1086
Shipley, M., 360
Shoji, S., 753
Shoji, T., 1178
Shomphe, L.A., 1122
Shraga, I., 506
Shubnikof, E.V., 563
The SID-AMD Italian Study Group for the Implementation of the St. Vincent Declaration, 1439
Sieslack, S., 1505
Sievenpiper, J.L., 711
Silberbusch, J., 216
Silbert, C.K., 510, 574, 669
Silveiro, S.P., 1521
Silverman, B.L., B142
Silverstein, J.H., 213
Simeone, L.R., 1339
Simkins, S., 93
Simó, R., 866
Simon, I., 463
Simons, L.A., 695
Simonson, D.C., 1330, C44
Simpson, J.L., 1978
Sims, E.A.H., 467
Singh, B.M., 1567
Sivan, E., B118
Slaats, E.H., 216
Slama, G., 717, 867
Sloan, R.P., 2116
Smakowski, P., 1339
Smidt, U.M., 804
Smiell, J.M., 822
Smith, N.L., 1117
Smith, P.J., 1030
Smith, S.A., 972
Smith, T., 1511
Smits, P., 796, 2202
Smulders, R.A., 99
Snehalatha, C., 76, 666, 967, 1205
Snoek, F.J., 919, 1568, 2039, 2085
So, W.-Y., 1221
Soininen, H., 398
Soler, J., 62
Sommariva, D., 1397
Soskin, S., 1146
Souvatzoglou, A., 2111
Sowers, J.R., 2103
Spallino, L., 1567
Spalluto, A., 104
Spector, T.D., 2069
Speer, G., 1778
Spichler, E.R., 1246
Sprecher, E., 506
Stabilini, L., 1101
Stabilini, M., 1101
Stacpoole, P.W., 1587
Stalenhoef, A.F.H., 796, 2202
Stamatelopoulos, S.F., 2111
Standl, E., 1044
Stehouwer, C.D.A., 99, 1686
Steiner, G., 2039
Steinke, D., 738
Stenström, G., 546
Stephure, D.K., 1985
Stern, M.P., 1167, 1266
Sterzi, R., 1777
Stessman, J., 2030
Stewart, C.P.U., 738
Stirling, H.F., 1567
Stoney, R.M., 828
The STOP-NIDDM Trial Research Group, 1720
Strachan, M.W.J., 26, 470
Strack, T., 93, 1627
Strange, P., 1897
Strogatz, D.S., 555
Strollo, F., 597
Strollo, G., 597
The Strong Heart Study Investigators, 1258
Strowig, S.M., 1694
Strugger, M., 915
Stuckens, C., 1146
The Study Group, 477
Stumvoll, M., 1505
Su, Y., 822
Sugarman, J.R., 777
Sullivan-Bolyai, S., 902, 909
Sun, W., 525
Sundkvist, G., 250, 546
Susa, S., 1525
Sussman, A., 2050
Suzuki, Y., 1373, 2037
Swinn, R., 668
Swislocki, A.L.M., 677
Szekeres, O., 1778
Şahin, G., 2033

T

Taboga, C., 1529
Tack, C.J.J., 796, 2202
Tajima, H., 2016
Tajima, N., 1674
Takahashi, H., 2140
Takahashi, T., 1495
Takaike, H., 1080
Takamasu, M., 320
Takanashi, Y., 615
Takano, Y., 2123
Takei, S., 1569
Takemura, Y., 1173
Takeuchi, H., 2140
Tam, S.C.F., 1154
Tamborlane, W.V., 817, 902, 909
Tamez-Pérez, H.E., 873
Tan, M.-H., 139, 1612
Tanaka, K., 2034
Tanaka, S., 323, 482, 1353
Tanaka, Y., 116, 1133
Tanimoto, T., 1014
Taniwaki, H., 1848
Tarnow, L., 804, 1534
Tattersall, R.B., 341
Tatti, P., 597
Tauber, J.-P., 977
Taylor, H.R., 324
Taylor, K., 668
Taylor, T., 1288, 2050, 2056
Tenore, A., 38
Tercyak, K.P. Jr., 213
Testa, M.A., C44
Teuscher, A.U., 1944
Thaler, L.M., 1576
Thiella, G., 1777
Thivolet, C., 322, 2192
Thomas, A.J., B85
Thomas, W., 1110
Thompson, R.G., 987
Thompson, T.J., 1030
Thon, A., 671
Thureen, P.J., B70
Tikkanen, M.J., 477
Tildesley, H.D., 93, 1627
Timsit, J., 191, 1371
Ting, C.-T., 1743
Tiu, S.C., 1154
Tkac, I., 1749
Tohda, G., 1774
Tohjima, T., 116
Toivanen, L., 949
Tollios, J.L., 725
Tomar, R.H., 725
Tominaga, Y., 256, 1206
Tomonaga, O., 2144
Tonutti, L., 1529
Tooke, J.E., 2047
Torjesen, P.A., 1997
The Toronto Tri-Hospital Gestational Diabetes Investigators, B33
Torres, M., 2029
Torri, A., 1397
Tötterman, K.J., 1932
Trajanoski, Z., 585
Trief, P.M., 241
Trimble, E.R., 677
Trinkaus, K.M., 2062
Tritschler, H.J., 1295, 1310
Trivin, F., 463
The Troglitazone Study Group, 1455, 1462
Trovati, M., 121
Trucco, M., 1824
Trussell, R.A., 1985
Tsai, S.-T., 1183
Tsang, L.W.W., 1221
Tsang, M.W., 1154
Tsuchiya, T., 1470
Tsui, E.Y.L., 93
Tsukada, Y., 1027
Tudor, S.M., 53
Tuomilehto, J., 69, 949, 1101, 1349
Tuomilehto-Wolf, E., 949
Tuominen, J.A., 1345
Turner, K.J., 1029
Turner, R.C., 810, C35
Turner, R.R., C44

Turpeinen, A., 1861
Tyler, B., 1306

U

Uchigata, Y., 1080
Uchimura, K., 672
Ueda, H., 1086
Ueki, Y., 256, 673, 1206
The U.K. Insulin Aspart Study Group, 1904
U.K. Prospective Diabetes Study Group, 87, 1271
Uusitupa, M.I.J., 1861
Uysal, A.R., 2033

V

Vaag, A., 1489
Vaccaro, O., 649, 2041
The VA CSDM Group, 510, 574
Vadheim, C.M., 80
Vague, P., 1967, 2041
Valensi, P., 1008
Valerio, G., 38
Valle, T., 949
Valsania, P., 1828
Vámosi, I., 1019
Vanasia, A., 104
Van Buuren, S., 190
van der Does, F.E.E., 2085
van der Veer, N., 1568
van Domburg, R.T., 1797
van Haeften, T.W., 278, 673
Vanhanen, M., 398
van Schie, C.H.M., 1955
Van Vorst, K.A., 2062
Vardi, P., 506
Varli, K., 1915
Vassault, A., 265
Vasudev, N., 738
Vázquez-Lara, J., 873
Vega, J.L., 2029
Venable, T.C., 1462
Venditti, E., 350
Vendrell, J., 463
Veneman, T.F., 1939, 1960
Venkat Narayan, K.M., 1370, 1432
Verrotti, A., 2003
Veves, A., 1339, 1714
Vidal, H., 717
Vidgren, G., 949
Vijay, V., 666, 967, 1205
Vileikyte, L., 1071
Villa, G.M., 104
Viñes, G., 1577
Vinicor, F., C15
Viscardi, M., 1226
Viswanathan, V., 76
Vitelli, L.L., 324
Vonk, P., 1481
Vonk-van Klei, Y., 1481
Vuksan, V., 711
Vukusic, B., 1571

W

Wach, P., 585
Waclawiw, M.A., 1589
Wagener, R., 1110
Wagenknecht, L.E., 1790, 1812
Wagner, E.H., 2062
Wagner, J.A., 1046
Wagner, R., 1110
Wagner, A., 1572
Wahl, P., 841, 1310
Wahl, P.W., 1117
Wai, H.P.S., 1221
Wakisaka, M., 516
Walker, E.A., 320
Walker, J.D., 199, 374, 535
Walker, K.Z., 828
Wang, K., 525
Wang, P.H., 1743
Wang, X., 1774, 2195
Wannamethee, S.G., 732
Wareham, N.J., 668
Warne, G.L., 379
Watanabe, C., 1080
Watanabe, M., 2140
Watanabe, R.M., 949
Weber, J.A., 216
Wei, M., 1167
Wein, W., 570, 1778
Weinstock, R.S., 241, 368, 1029
Weir, D.G., 1843
Weiss, N.S., 1117
Weiss, S.R., 1288, 2056
Weitgasser, R., 462
Weller, W.E., 747
Welty, T.K., 1258
Wen, M.-J., 1856
Werle, E., 994
Werther, G.A., 379
Weschler, J.M., B123
Westphal, S.A., 1619
Weyer, C., 800, 1910
Whitcomb, R.W., 1455, 1462
Whitehouse, F., 1462
Wiart, J., 1775
Wiedmeyer, H.-M., 518
Wieliczko, M.-C., 1146
Wieman, T.J., 822
Wientjes, K.J., 1481
Wiggam, M.I., 677
Wijkel, D., 919
Wilcken, D.E.L., 1774, 2195
Wiley, T.L., 1540
Wilhelmsen, L., 539
Willeit, J., 221
Williams, D.E.M., 668
Williams, G.C., 1644
Williams, G.R., 1699
Williams, K.L., 1266
Williams, K.V., 2
Williamson, D.F., 1432
Williamson, S., 1071
Willmer, A.J., 770
Wilson, P.W.F., 1585
Wing, R.R., 2, 350
Wingard, D.L., 1652
Winkler, G., 1778
Wishner, W.J., 1240
Wither, J., 1571
Wolever, T.M.S., 322, 336, 667, 1612
Wolf, A., 671
Wolfel, E.E., 291
Wolff, S.P., 1295
Wong, E.Y.Y., 711
Woo, J., 2094
Wood, C.A., 324
Woodworth, J.R., 800, 2098
Wrathall, K., 1579
Wright, A.W.D., 874
Wroblewski, M., 250
Wu, C.-J., 1575
Wu, G.-S., 1183
Wu, J.-S., 1856
Wu, S.-Y., 725
Wutte, A., 585
Wylie-Rosett, J., 334

X

Xiang, A., B50, B99

Y

Yamada, H., 1080
Yamada, K., 753, 1086
Yamada, N., 192
Yamaguchi, Y., 256
Yamakido, M., 1451
Yamakita, T., 1353
Yamamoto, M., 1451
Yamanouchi, T., 619
Yamasaki, Y., 2123, 2135
Yamashita, K., 199
Yamatani, K., 1525
Yamauchi, M., 323
Yang, Y.-C., 1856
Yang, Z., 525
Yano, M., 256, 673, 1206
Yano, N., 2144
Yarbrough, D.E., 1652
Yasuda, T., 1027
Yazaki, Y., 192
Yeh, J., 563
Yeung, V.T.F., 1221
Yokoo, S., 1206
Yokota, I., 49
Yokoyama, H., 1080
Yoon, Y.-H., 134, 2149
Yoshida, T., 320, 465, 1206
Yoshimura, T., 619
Yoshinari, M., 516
Yoshino, G., 2016
Yoshioka, K., 465, 482, 1206
Yosipovitch, G., 506
Young, B., 930
Young, J.B., B156
Young, R.P., 431
Young-Hyman, D., 1870
Yu, C., 902, 909
Yu, Z.-W., 1217
Yuan, X., 753
Yudkin, J.S., 127
Yung, B., 2199

Z

Zaini, A., 385
Zampolli, M., 1567
Zelmanovitz, T., 1076
Zhang, J.X., 1090
Ziegler, A.-G., 1573
Ziegler, R., 841, 1310
Ziemer, D.C., 501, 1576
Zieve, F.J., 368, 1596
Zilvitis, B., 1775
Zimmerman, B.R., 972
Zinman, B., 93, 322, 851, 870, 874, 1203, 1627
Zirinis, P., 867
Zonderland, M.L., 278
Zuccala, G., 193
Zumbach, M.S., 841